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Abstract 
Considerable efforts have been made to fabricate nano-sized drug delivery systems (DDS) 
with unique and advanced features in comparison to conventional DDS. Yet, challenges still 
lay ahead requesting for more controllable, even on-demand drug release profiles from the 
DDS. Moreover, the emerging concept of personalized treatment further urges the 
combining of therapy and imaging regimes into a single nanocarrier. 
Among all the nanomaterials studied so far, porous silicon (PSi) draws increasing 
interest for constructing DDS due to its good biocompatibility, non-immunogenicity, large 
pore size/surface area and easily changeable surface properties. Herein, the aim of this thesis 
was to explore PSi-based DDS for multiple biomedical applications, which were designed 
and synthesized with specific on-demand features. Moreover, simultaneous incorporation 
of imaging modalities and drugs enables real-time visualization of drug release and/or 
cellular/tissue level disease condition, which are expected to be beneficial for personalized 
treatment regime. 
First, the potential of PSi nanoparticles for hydrophilic drug loading and on-demand 
release were evaluated by adapting a dynamic non-covalent bonding method. Different 
ligands were synthesized and applied for modifying the PSi, and the hydrophilic anti-cancer 
drug doxorubicin (DOX) was sequentially loaded into the fabricated DDS for pH-
responsive release profiles. Meanwhile, the fluorescence spectrum of DOX can be 
dynamically shifted or quenched, depending on the loading and releasing process, thus 
facilitating the in situ visualization of the drug releasing process. 
For hydrophobic drugs, a physical encapsulation method was applied to seal the pores 
of the PSi by a polymeric matrix. Microfluidic-assisted nanoprecipitation method was 
applied to synthesize batches of nanohybrids with identical PSi-core/polymer-shell 
structures, and the release behavior was feasibly tailored by the degradation behavior of the 
outer polymeric matrix. The first trial was set to fabricate a core/shell nanohybrid, with PSi 
and gold nanoparticles co-encapsulated in a pH-responsive polymer to simultaneously 
deliver hydrophobic drug and increase the computed tomography signal for acute liver 
failure theranostics. The newly established single-step co-encapsulation of different 
particles endowed a system with multi-functionalities, and the polymeric shell precisely 
tailored the drug release behavior in a pH-dependent manner. Similarly, an acid/oxidation 
dual-responsive polymer was designed and further applied in encapsulating atorvastatin-
loaded PSi nanoparticles. The meticulously designed system not only obtained a dynamic 
drug release behavior, but also showed an orchestrated cascade that facilitated bio-mimetic 
diabetic wound healing.  
To better elucidate the biocompatibility of PSi for DDS fabrication, the biological effects 
and immunogenicity of different PSi nanoparticles were evaluated at pre-existing lesion 
sites, which provided insights for further applications of PSi in DDS fabrication. 
In conclusion, multiple PSi-based nanohybrids with different on-demand responses were 
fabricated and applied as DDSs for different diseases. The newly developed nanosystems 
tailored drug release and obtained multiple modalities, ranging from real-time bio-imaging 
to bio-mimetic/bio-response alteration, as such, represent promising platforms for future 
therapy regimes. 
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1 Introduction 
Meticulously engineered drug delivery systems (DDS) are pivotal for the targeted delivery 
and/or controlled release of therapeutic agents.1 Comparing to new pharmaceutical agents 
development, the combination of a “smart” delivery system with tailored spatiotemporal 
release behavior is equally indispensable to the development of new pharmaceutical agents, 
and has been pursued vigorously for the past decades.2, 3 The application of biomaterials to 
fabricate DDS is ubiquitous in the practice of medicine, yet the intrinsic limits of 
conventional DDS, such as unregulated drug bio-distribution, detained hydrophobic drug 
diffusion/release and unfavourable release profile,4, 5 prompt the development of new 
generation DDS for more effective and safer treatments. 
Nanoparticles (NPs) based DDS have emerged as suitable drug delivery vehicles for 
overcoming pharmacokinetic limitations associated with conventional drug formulations by 
showing advantageous in solubilizing hydrophobic therapeutic cargos and further 
enhancing their diffusion behavior, and prolonging the circulation lifetimes of drugs in the 
bloodstream.5-7 Due to the large surface-to-volume ratio, nanoparticles can be feasibly 
surface-modified with proper ligands to obtain multi-functionalities. Therefore, the concept 
of “one particle performs multiple functions” can be concurrently achieved.8, 9 In addition, 
unique nano-scale size endows the DDS with the ability to increases the DDS accumulation 
at specific sites, such as tumor or inflammation spots, while promoting intracellular 
penetration.10-12 
Among the biomaterials studied so far, porous silicon (PSi) NPs have attracted 
increasing attention for potential biomedical applications, especially as advanced DDSs.13, 
14 Their pore size (~10 nm) makes PSi very flexible in loading different kind of cargos, 
ranging from small molecule drugs, proteins, peptides, RNA to other NPs.15, 16 The versatile 
surface chemistry and high surface area (up to 1000 m2/g) enables PSi to be feasibly surface 
functionalized for multiple purposes. Moreover, PSi has good biocompatibility and 
biodegradability; it is degraded into non-toxic orthosilicic acid in vivo, and the degradation 
rate can be feasibly tuned by altering the overall size, porosity, pore size and surface 
functionalization.17, 18 All these features render PSi NPs a perfect candidate for fabricating 
DDSs. 
However, due to the freely accessible pores of PSi, the loaded drugs can be disrupted by 
body fluids, leading to burst release and/or inactivation of the loaded cargos.19, 20 Moreover, 
despite previous investigations, precise control of drug release at localized sites of interest 
remains a critical challenge.21-23 Proper methods should be considered to fabricate PSi-based 
DDS that can recapitulate the heterogenous native microenvironment and further release 
drug(s) at desired sites to increase therapeutic efficacy. 
Spurred by recent progress in materials chemistry, one alternative that is gaining 
attention in DDS construction involves on-demand processes.24, 25 On-demand, or stimuli-
responsive drug delivery systems can recognize their surrounding microenvironments, 
further undertake structural or functional alteration, mimic the responsiveness of living 
organisms or release the loaded cargo in the lesion sites.9, 26, 27 Yet, different strategies 
should be prudently selected for drugs with different physiochemical properties and 
different biomedical applications. 
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For hydrophilic drugs, a facile method to effectively control the release kinetics is by 
chemical conjugation, whereas the inherent defects of covalent bonding, ranging from 
organic solvents introduction, deactivation of the cargos, to unfavourable selectivity of the 
reaction site, may perturb the envisioned design.28, 29 Next-generation DDS fabrication is 
based on the introduction of cleavable motifs by reversible non-covalent interaction that 
exploits metal chelation, coordination, hydrogen bond, π–π stacking, hydrophobic 
interaction and/or Van der Waals interactions.30-35 The cleavable moieties can be triggered 
by specific stimuli, therefore achieving the preferred release performance. 
For hydrophobic drugs, the interaction between PSi with the hydrophobic surface may 
render the drugs to reside in the pores of PSi,36 while the following surface encapsulation 
can effectively seal the pores to prevent uncontrollable release and payload inactivation 
when interacting with body fluids.37 Therefore, the judicious choice of encapsulating 
materials is one of the key preconditions for successful construction of DDS, and is highly 
implicated with different biomedical applications, thus needing further investigation. 
Meanwhile, an advanced encapsulating methodology is another pivotal factor impinging on 
successful and efficient DDS fabrication. Microfluidics has had a revolutionary impact on 
a wide range of applications, such as colloidal particle fabrication, chemical synthesis, tissue 
engineering and biological simulation/analysis.38-41 The specific benefits of microfluidic-
assisted encapsulation arise from fluid flow manipulation, which confers to the control over 
shape, size, geometry, the loading of different cargos, and release profiles of the DDS in a 
tailored manner.42, 43 Therefore, this platform can be leveraged to create a series of advanced 
DDS, such as single, double and higher-ordered emulsions, microcapsules, 
NPs/nanohybrids and other colloidal DDS.44, 45 As such, microfluidics platform provides a 
diverse toolbox that can help address unmet biomedical needs. 
Upon such consideration, in this dissertation, we focused on the fabrication and 
characterization of multiple therapeutics loaded PSi-based DDS with on-demand control 
over the drug release, and evaluating their different biomedical applications. Both 
hydrophilic and hydrophobic drugs were applied in the studies and different strategies were 
utilized, corresponding to the physiochemical properties of the loaded cargos. Stimuli 
responsive dynamic non-covalent bonds were leveraged for controlling the release of 
hydrophilic drugs, which were endowed by the design and/or application of different ligands. 
For hydrophobic drugs, microfluidic-assisted nano-encapsulation was carried out to 
fabricate PSi-based nanohybrids (drug loaded PSi as core and functional polymer matrix as 
shell) to avoid the premature release of payloads, allowing the on-demand release of the 
cargos at desired times and sites. Multi-functionalities, such as drug release tracking or bio-
imaging, were synchronously achieved to further explore the cutting-edge functions of 
nanotechnology. Most importantly, the biocompatibility and immunogenicity of PSi under 
pathological condition were investigated to better evaluate the biosafety of the DDS, 
offering significant insights for further clinical translation. 
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2 Review of the literature 
2.1 Multifunctional on-demand DDS 
Advanced NPs-based DDS have drawn tremendous attentions in recent years. The interest 
was initiated by the enhanced accumulation of NPs at specific sites, such as tumors or 
inflamed tissues.46-48 In addition, the intrinsic nature of nano-sized carriers can solve some 
of the refractory drawbacks of conventional DDS, such as enhancing the pharmaceutical 
properties of the drugs, e.g. stability, solubility and longevity, while providing simultaneous 
imaging or diagnosing capabilities and real-time visualization of drug delivery sites.49-52 
However, despite the development of a broad range of NPs, including liposomes, polymer 
NPs, micelles, dendrimers, origami DNA, drug crystals and inorganic NPs, the overall 
picture of the further applications of NPs-based DDS is still blurred by many challenges 
inherently linked to the complexity of disease pathophysiology and a series of physiological 
barriers.53-56 Consequently, the difficulty  in controlling drug release from NPs further 
motivates the rational design and architecture fabrication of nanomedicine to overcome the 
challenges.57, 58 
A fundamental goal for nanomedicine is to prevent the payloads from any passive 
leakage in the delivery process, but also to readily unload the cargos in a controlled manner 
once arriving at the target sites.27 To achieve this spatiotemporal controlled release, on-
demand or stimuli-responsive NPs have been proposed for various therapeutic cargos.59, 60 
These dynamic NPs are capable of recognizing, adapting and responding to a variety of 
stimuli, followed by morphology transformation or degradation of the NPs to induce the 
release of drugs. 
Furthermore, to explore the multi-functionalities of the on-demand DDS, one cannot 
discard the possibility of simultaneously applying the DDS for imaging or diagnosis.61, 62 
The prudent choice of loaded cargo or surface modification may provide theranostic 
applications, including bio-imaging facilitated diagnosis, cellular imaging, and real-time 
drug release monitoring.  
2.1.1 On-demand DDS for controlled release 
Two categories of stimuli triggered drug release profiles can be briefly divided depending 
on the stimuli source. Endogenous stimuli triggered on-demand DDS refers to trigger by 
abnormal or unique physiochemical microenvironments at the target sites,63-65 whereas 
exogenous stimuli triggered on-demand DDS leverages externally applied stimuli, such as 
light, temperature, magnetic field and/or ultrasound to initiate the dynamic transformation 
of the NPs.64, 66 In the interest of brevity, this thesis does not included exogenous stimuli 
triggered on-demand DDS. Instead, the focus is on design strategies and exploiting the 
subtle environmental changes associated with pathological situations. 
Aberrant physiological characters within the diseased tissue or specific cells are 
ubiquitous, and can therefore be exploited to fabricate on-demand DDS. Implementation of 
a viable system is vastly dependent on the judicious choice of applied stimuli and 
methodologies, which are implicated with different biomedical applications and 
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physiological properties of the loaded drugs. The following sections will briefly review the 
commonly used on-demand NPs constructions and their potential biomedical applications. 
2.1.1.1 pH-Responsive DDS 
pH variation widely exists throughout the human body (Figure 1). This phenomenon is 
observed on the organ level (e.g., altered pH-values in gastrointestinal tract and vaginal 
cavity), tissue level (e.g., decreased pH-values within the extracellular matrix (ECM) of the 
tumor) and cellular level (e.g., acidic environments within endosomal/lysosomal system). 
As such, pH may play a salient role in the on-demand DDS design. 
 
Figure 1. Schematic representation of two strategies applied for fabricating pH-responsive DDS 
and corresponding potential biomedical applications in different diseases. Figure 
adapted and reprinted with permission from Ref. 67. 
One vigorously pursued area for acidic-sensitive DDS is cancer therapy. One of the 
hallmarks for tumor extracellular microenvironment is the overall decrease in pH-value 
compared to healthy tissue.68 Tumor acidosis is generally related to hypoxia as a result of 
irregular angiogenesis induced poor perfusion.69 This shifts the metabolic behavior of the 
cells from aerobic oxidation to glycolysis, generating a plethora of lactate. Simultaneously, 
the up-regulated expression of hypoxia inducible factor 1α (Hif-1α) can favor the passive 
release of lactate out of the cells, with the efflux of H+, thus enhancing the acidification of 
the extracellular milieu.70 The acidosis phenomenon is further exacerbated  by the 
overexpression of carbonic anhydrases (CA) families, in particular extracellularly located 
CA IX, which hydrate CO2 through the action of CA IX to generate H
+ and HCO3
− and 
vented to the extracellular environment, further exacerbating the acidosis phenomenon.71 
Acidic-responsive on demand DDS can also be applied in anti-bacteria therapy. 
Bacterial infection is one of the most refractory complications for tissue engineering. With 
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the impetus to study bacterial metabolism, acidosis is becoming increasingly recognized as 
a unique feature of bacterial infection, as bacterial growth will generate acidic products, 
such as carbonic acid and lactic acid, during respiration and fermentation, yielding an acidic 
microenvironment.72, 73 
The pH-responsive strategy can be applied at cellular levels as an intracellular specific 
drug delivery platform. A well-established phenomenon is the acidic condition within the 
endosomal/lysosomal system.74 Depending on the particle size and surface treatment of the 
DDS, it may enter the cells via different pathways, including phagocytosis, 
macropinocytosis, caveolin-mediated, clathrin-mediated and receptor-mediated 
endocytosis.75 For nano-scale DDS, the dominant route for intracellular transport is cellular 
endocytosis, which initiates with the formation of early endosomes and ends up in 
lysosomes with acidic pH-values (pH 46).76 Therefore, an acidic-sensitive platform may 
enable the endocytosis responsive drug release and substantially help in obtaining potential 
cellular imaging capabilities. 
In spite of the multiple biological applications, the strategies or materials applied to 
fabricate pH-responsive DDS can be briefly divided into two categories. One is by 
employing pH-responsive non-covalent bonding, which can be dynamically disrupted by 
protonation or deionization under acidic environment, for example by introducing pH-
responsive metal chelation or coordination bonds. Metal ions often exist as electron-
deficient cations, and hence, are attracted to electron-rich molecules, such as proteins, DNA 
or other active pharmaceutical agents. Under physiological conditions, a deprotonated 
chelation center, which usually contains oxygen or nitrogen, can be generated with high 
charge density, therefore effectively coordinating with the metal, whereas the proton is 
displaced at lower pH-values, yielding an acid-triggered release.77-79 For example, 
doxorubicin (DOX), a widely used chemotherapeutic agent for cancer therapy, is vastly 
presented as a DOX-iron (III) complex in biological systems.80 Due to the alkaline nature 
of DOX with a pKa around 7.6–8.3, it will show a detained protonation level at 
physiological conditions, steadily coordinated with iron, whereas this chelation can be 
broken under acidic conditions due to the protonation of DOX.81, 82 Upon such 
considerations, Liu et al. constructed an iron silicate based nanosystem through a silica 
template sacrificing method. The newly constructed NPs with enriched ferric ions on the 
surface could efficiently coordinate DOX, further achieving a pH-responsive release 
profile.83, 84 In addition to coordination bonds, this protonation/deprotonation mechanism 
can also be feasibly transferred to hydrogen bonds or hydrophobic interactions. For example, 
chitosan, a widely used pH-sensitive polymer, can dissolve under acidic conditions due to 
the protonation of the amine groups, while it can precipitate and encapsulate multiple drugs 
at pH-values higher than 6.5 because of the hydrogen bonding between the hydroxyl and 
uncharged amine groups.67, 85 Acidic pH-induced protonation brings forth a hydrophobic–
hydrophilic phase transition for cationic polymers.86, 87 Wu et al. prepared a poly[2-
(diisopropylamino)ethyl methacrylate] (PDPA) containing amphiphilic block copolymer 
with a pKa ∼6.2. The block copolymer self-assembled into nano-micelles with a 
hydrophobic PDPA core for tight encapsulation of hydrophobic drugs via hydrophobic 
interaction. This bonding interaction was interrupted upon exposure to an acidic 
environment due to the protonation of PDPA block, transforming the copolymer 
amphiphilicity to double hydrophilicity.88 Similarly, the protonation/deprotonation process 
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may also alter the surface charge of the colloidal particles, and the reversible charge can 
induce drug release via disturbing the electrostatic interactions.89, 90 Overall, the 
aforementioned strategies leverage non-covalent bond disruption as a result of pH variation 
induced protonation/deprotonation and initiate the drug release at the desired site. 
The second strategy to fabricating pH-responsive DDS is by utilizing acid-liable 
covalent bonds. So far, the most commonly used acid-liable covalent bonds include 
citraconic amide,91 imine or benzoic-imine,92 hydrazone,93 ketal/ acetal and/or cyclic 
acetal94 and ortho ester.95 Drugs can either directly conjugate on the polymer backbone or 
side chains through labile bonds, or be encapsulated inside the carriers, which incorporating 
the corresponding bonds. The choice of the bond or materials is largely dependent on the 
requirement for drug release behavior. For example, hydrolysis of hydrazone or acetal is 
rather fast. Therefore the drug can be completely released within hours to a few days, 
whereas cleavage of imine or ester linkages are usually slow, which is beneficial for 
continuous and prolonged release. For example, Liu et al. encapsulated drug loaded porous 
silicon (PSi) NPs with acetalated dextran (AcDEX), where upon exposure to an acidic 
environment, the acetal bonds were hydrolyzed, rendering the hydrophobic AcDEX to 
degrade into hydrophilic dextran. Therefore, nearly 100% of the loaded drug (methotrexate) 
was burst-released within 5 h at pH 5.96 Hu et al. reported a smart aminoglycoside DDS that 
conjugated antibiotics via the imine bond to demonstrate a pH-responsive on-demand drug 
delivery system. Below a pH-value of 5.0 (simulating the bacterial infection environment), 
more than 80% of antibiotics were released within 3 days.92 The design of the materials 
should also be optimized depending on the biological conditions. Hydrazone has been 
extensively explored as a pH-responsive biomaterial. However, the hydrazone linkages with 
methyl on the nitrogen can only be hydrolized under a pH-value of 5, suggesting its potential 
application for intracellular drug delivery; hydrolysis of hydrazone linkages with 
acetaldehyde innitrogen readily occurs at pH 6, indicating its sensitivity towards the 
extracellular tumor environment.97 
2.1.1.2 Oxidation-responsive DDS 
Reactive oxygen species (ROS) often contain, or can be converted to contain, one or more 
unpaired electrons, and are therefore highly reactive and essential for biological functions 
by reacting with or modifying biological molecules, including DNA, proteins and lipids.98 
Examples of radical ROS include superoxide, nitric oxide, hydroxyl radicals, hydrogen 
peroxide and peroxynitrate. ROS may generate from the outer environment, such as 
oxidants from tobacco smoke or radiation; nonetheless, they are also endogenously 
generated from the activation of inflammatory cells by using predominantly nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidases.99 There is a delicate balance between 
the positive role of ROS (such as preventing pathogen infection, stimulating re-
epithelialization and facilitating extracellular matrix remodeling)100 and their deleterious 
effects under pathological conditions. However, chronic inflammation with long term 
exacerbation of NADPH oxidase activation may lead to excessive production of ROS, 
which further accelerates inflammation and oxidative stress.101 Former clinical studies 
suggest that diseases involving long-term prognosis, such as cancer,98 rheumatoid arthritis,99 
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diabetic wounds,101 or steatohepatitis,102  maintain highly oxidizing environments, which 
may lead to impaired treatment efficacy. 
Upon such considerations, fabricating on-demand DDS that could respond to exorbitant 
ROS conditions has immense potential in biomedical DDS development. Table 1 briefly 
summarizes commonly used ROS-sensitive moieties. One method is by introducing ROS 
cleavable moieties in the DDS. For example, phenylboronic acid ester (PAE) containing 
polymers have shown susceptibility towards H2O2. Gracia-Lux et al. catalyzed 
dimethylphenylboronic acid ester with benzylic bromination. The yielded compound was 
further functionalized as monomers to initiate step growth polymerization. As a result, the 
produced polymer showed a clear degradation at 1 mM H2O2 with 80% release of the loaded 
model dye within 20 h. However, the polymer has a relatively high polymer dispersity index 
(1.9), resulting in an overall low yielding degree. Meanwhile the absence of extra functional 
groups may further impinge on its biomedical applications.103 Broaders et al., directly 
modified a natural polysaccharide dextran with PAE to obtain a H2O2 responsive 
polymer.104 The newly synthesized polymer was prepared via a simple and facile method, 
and presented similar H2O2 sensitivities with full degradation at 1 mM H2O2. Nonetheless, 
the applied H2O2 concentration was a rather high dose and not biologically relevant 
Meanwhile, the oxidation was only initiated by H2O2 but not by other ROS, bringing forth 
further sensitivity concerns when considering in vivo applications. The sparing solubility of 
PAE-based polymers in various solvents further constrains the production of other 
formulations, and therefore a more deliberately designed system should be further 
conceived. 
Another commonly used mechanism for fabricating ROS-responsive DDS is inducing a 
solubility change under ROS irritation. This method typically uses sulfur (II) containing 
materials, particularly hydrophobic sulfide moieties that can be oxidized to hydrophilic 
sulfoxides and sulfones.105 The first demonstration of polyalkylene sulfide-based DDS were 
polymersomes formed by the triblock copolymer polyethylene glycol (PEG)-polypropylene 
sulfide (PPS)-PEG, which undertook a phase conversion of vesicles into micellar lyotropic 
aggregates at 0.03% of H2O2 (v/v), and showed a clear morphology change at 3% or higher 
H2O2 (v/v).
106 This inspired the formation of various sulfide containing polymers for ROS-
sensitive DDS.107, 108 The effective ROS concentration for the vehicle disruption, however, 
ranged from 110% H2O2 or 0.110 mM of 3-morpholinosydnonimine.109-112 Given the 
scarcity of extracellular ROS, they were more often applied as a carrier for vaccines due to 
the higher oxidative content within immune cells.113, 114 Despite the marginally robust 
incitement ROS concentration in vivo, one cannot deny the significance of such DDS 
complementing the useful array of pH-sensitive or other stimuli-responsive materials. Yet, 
to further explore versatility, the design and synthesis of a new ROS-responsive DDS should 
focus either on constructing biomaterials with higher sensitivity or engineering the DDS 
with a cascade ROS amplification capability, therefore reducing the required ROS 
concentration.115, 116 
Table 1. Brief summary of the oxidation-responsive motifs and their oxidation        
mechanisms. 
Responsive 
moieties 
Chemical 
structure 
Degradation mechanism Ref. 
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Phenylboronic 
ester   
103, 104, 
117, 118 
Alkyl sulfide 
 
 
110, 111, 
119 
Disulfide or 
diselenide 
  
119-122 
Thiolketal 
  
123-125 
Peroxalate 
  
126-128 
2.1.1.3 Glucose-responsive DDS 
High glucose levels are a pivotal factor of diabetes and may shed light on the DDS 
construction for diabetes and its corresponding complications.129 As a key energy supplier, 
a DDS that can both respond to glucose and also effectively consume glucose may further 
function as a starving-agent for some wasting diseases, such as cancer (Figure 2).130 Several 
glucose sensing moieties or compounds were evaluated for biomedical applications. 
Phenylboronic acid (PBA) is one commonly used synthetic moiety for constructing glucose 
responsive on-demand DDS.131 The inherent mechanism behind PBA facilitated glucose 
sensing is that PBA can be ionized with a hydroxide ion under aqueous conditions, and can 
therefore steadily react with 1,2- and 1,3-diols, such as glucose, allowing boronate ester 
formation. However, boronic esters have a pKa slightly lower than that of free boronic acids. 
As such, the binding of diols with boronic acids can shift the equilibrium from the neutral 
species to anionic boronate esters, resulting in solubility changes from hydrophobic to 
hydrophilic, and electrostatic interaction alterations.132 Langer et al. demonstrated a strategy 
for the chemical modification of insulin with a PBA containing aliphatic domain.133 The 
incorporation of the aliphatic domain can effectively enhance the longevity comparing to 
the native insulin, whereas the sequential inclusion of PBA modulated the insulin exposure 
through alteration of hydrophobicity and electrostatic interactions upon glucose binding. 
The new system enabled rapid reversal of blood glucose in a diabetic mouse model, 
following glucose challenge over 13 h, over a clinically used long-acting insulin derivative, 
showing great promise for sustained insulin release.  
Apart from synthetic moieties, natural glucose sensing proteins have also been explored 
for developing glucose responsive DDS. One example is integrating concanavalin A (ConA) 
in the DDS along with glycosylated insulin, which can effectively recognize and bind with 
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glucose.134 Based on this, Kim et al. encapsulated both ConA and glycosylated insulin in a 
polymeric membrane that was permeable to glucose but not to ConA; the competitive 
binding between the glycosylated insulin and glucose achieved a glucose-responsive insulin 
release.135  
 
Figure 2. Schematic illustration of two major strategies applied for constructing glucose-
responsive on-demand DDS, either by applying glucose binding moieties, such as PBA 
or ConA to alter the physiochemical properties of the DDS to induce the drug release, 
or by applying GOx to oxidize glucose to produce H2O2 and gluconic acid, further 
initiating the following cascade.  
Over recent years, glucose oxidase (GOx) has attracted increasing interest in the 
biomedical field due to its inherent biocompatibility, non-toxicity, and unique catalysis 
against D-glucose.136 GOx efficiently catalyzes the oxidization of glucose into gluconic acid 
and hydrogen peroxide (H2O2) and due to this unique feature, a multi-modal on-demand 
DDS was achieved by incorporating of GOx with pH-responsive or ROS-responsive DDS. 
Gu et al. recently reported a microneedle patch that integrated insulin loaded H2O2-
responsive NPs with GOx.117, 137, 138 By virtue of the generated H2O2 from GOx, the insulin-
loaded NPs disassembled and subsequently released the preloaded insulin. In vivo studies 
showed a three-fold longer effective time in maintaining normoglycemia comparing to the 
native insulin counterpart.117 The inspiring results indicated the potential success of 
applying GOx in other diabetes complications. However, corresponding formulation design 
and manipulation should be further considered, for GOx-containing bulk hydrogel usually 
exhibits insensitive response to glucose,139 whereas GOx-containing membranes suffer from 
low mechanical strength, which can result in premature leakage of the drug.140 A viable 
design should be further purposed according to specific disease condition and formulation 
requirements. 
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2.1.2 On-demand DDS for imaging 
Imaging based techniques provide simple and powerful approaches to examine organ/tissue 
pathological changes, cellular trafficking of the DDS, or microenvironment variations of 
the targeting tissues or cells.141 However, imaging or real-time imaging with high resolution 
remains a critical challenge. With the advent of cutting-edge nanotechnology, NPs serving 
as contrasting/imaging agents vastly promote this imaging possibility and efficacy. 
Integrating on-demand DDS with contrasting/imaging agents may provide a multipurpose 
system that has the ability to elucidate subtle, real-time changes within targeted sites, while 
simultaneously delivering the therapeutic.  
2.1.2.1 On-demand DDS facilitated cellular imaging 
Sensors that perform time-resolved measurements of intracellular metabolite levels are in 
great demand, as they can be used in biomedical diagnostics and to monitor biological 
processes, thus enhancing our general understanding of subtle biological changes. 
Fluorescence imaging allows direct, non-invasive yet effective monitoring of cellular 
behavior in real time. Compared to free dye, fluorescence sensors based on nanoscale 
biomaterials can reduce photo-bleaching,142 prolong cellular retention and enhance local 
fluorophore intensity.143, 144 Furthermore, sensors with the ability to alter fluorophore 
features under specific biological conditions, known as on-demand sensors, can monitor 
dynamic intracellular changes. This feature has particular significance for DDS evaluation, 
as it provides a valuable tool to visualize intracellular drug release or confirm the proposed 
formulation design, and hence, can preliminary evaluate the DDS design feasibility and 
performance. 
Briefly, two types of fluorescence characteristic changes can be applied. The first 
strategy relies on fluorophores’ intensity change in response to different stimuli. For 
example, quercetin, a natural anti-cancer flavonoid, is described to have the capability to 
exert such a function.145 Quercetin shows a clear fluorescent feature, however, due to the 
anthocyanidins ring structure within quercetin, when they are compacted or conjugated with 
another fluorescent compound, or quercetin itself, both the fluorescence signals can be 
effectively quenched through an electron transfer mechanism.146-148 Based on this, Wu et al. 
developed glutathione (GSH) sensitive NPs DDS based on quercetin.34 Two quercetin 
molecules were connected via a disulfide bond, which was cleaved upon contact with GSH. 
Then disulphide-bridged quercetin (QSSQ) was self-assembled into NPs via a precipitation 
method. Both the newly formed NPs and free QSSQ did not show significant fluorescence 
(Figure 3A). Facilitated by this feature, they observed both real-time GSH-dependent drug 
release, and also screened the GSH overexpression cancer cells, providing a useful tool for 
evaluating the metabolism of different tumors and facilitating a personalized treatment 
(Figure 3B,C). 
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Figure 3. Fluorescence based on-demand imaging can be briefly divided into fluorescence 
quenching or fluorescence spectrum changes. (A) Emission spectra for free quercetin 
(blue line), QSSQ (black line) and QSSQ NPs (red line). Excitation wavelength: 485 
nm. (B) The on-demand fluorescence quenching can be applied to monitor the drug 
release. (C) Screen of the GSH expression level for different cancer cell lines. (D) 
Schematic representation of the FRET design and mode of action of the system, 
including excitation (Ex.) and emission (Em.) wavelengths. Figures A-C are reprinted 
with the permission from Ref. 34. Figure D is reprinted with the permission from Ref. 
149. 
The second strategy relies on the fluorophores’ spectral shift in response to different 
stimuli. Implementation of this phenomenon can be achieved by applying the fluorescence 
resonance energy transfer (FRET) effect. FRET is the physical process by which energy is 
transferred from the emission light of one chromophore (donor) to another chromophore 
(acceptor).150, 151 The FRET efficiency is dependent upon the distance between donor and 
acceptor molecules (r): EFRET = 1/[1 + (
𝑟
𝑅0
)
6
], where R0 is the characteristic distance at 50% 
FRET efficiency.152 Because the efficiency is reduced with the sixth power of r, the FRET 
efficiency steeply drops off once the distance between the two fluorescent molecules 
exceeds R0. Due to this property, FRET can be feasibly applied to monitoring the release of 
the drugs, especially drugs with distinct fluorescent spectrum such as DOX, from the 
DDS.153, 154 Nagel et al. constructed a DOX (donor) loaded pH-responsive DDS with 
different acid-labile bonds, and further conjugated the fluorophore indodicarbocyanine 
(acceptor dye) in close proximity to DOX to fabricate a FRET complex.149 The newly 
constructed system can observe the DOX release through real time spectral changes and 
evaluate the sensitivities of different acid-liable bonds, providing basic knowledge for 
further DDS design (Figure 3D). 
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2.1.2.2 On-demand DDS facilitated bio-imaging diagnosis 
The accumulation of NPs at desired sites may further endow the sites with distinct 
features when comparing to surrounding tissue, and may therefore function as contrasting 
agents for bio-imaging facilitated diagnosis.155 For example, iron oxide-based NPs can be 
applied to magnetic resonance imaging (MRI) due to its paramagnetic or superparamagnetic 
property;156 the unique physical and optical properties, such as strong X-ray attenuation, 
photothermal capability and enhanced surface resonance emission of gold nanoparticles (Au 
NPs) have led to various schemes for developing Au NPs as a contrast-enhancing agent for 
computed tomography (CT) imaging, photoacoustic imaging and Raman imaging.157-159 
However, in vivo performance of bare NPs as a contrasting agent is usually unsatisfactory. 
This is mainly due to the heterogeneous biological environment, which usually brings 
contradictions for NPs design, ranging from size and surface charge to surface modification 
(Figure 4).53, 160 For example, the optimal NP size may shift during the NP transporting 
process. Several studies have demonstrated the feasibility of applying CT imaging to track 
monocyte recruitment to tissue plaques using Au NPs; however, too small NPs (< 5 nm) 
suffer from rapid clearance by renal filtration, leading to low plaque accumulation, and they 
also tend to show limited monocyte phagocytic system (MPS) uptake, resulting in an 
unsatisfied lesion tracking ability.161, 162 Larger NPs (> 150 nm), despite their favourable 
MPS uptake and contrasting ability, can hardly be excreted from the body and show higher 
cellular toxicity.163 Another example comes from the surface modification, Au NPs 
modified with PEG can enhance their stability and longevity, thus have higher chance to 
reach to lesion sites, whereas the PEG modification can hinder the tissue penetration and 
renal clearance of Au NPs, as such affecting imaging efficiency and biocompatibility.164, 165 
On-demand strategy aims to recapitulate the specific environment and change their 
properties accordingly, and thus may also be incorporated in the fabricated contrasting agent. 
Upon such considerations, various on-demand NPs are constructed and applied to 
enhancing imaging capabilities. Three major disciplines are widely applied, including size 
alteration, surface charge reversion and surface ligand activation/cleavage.160 The 
manipulation of size can widely impact the bio-distribution and bio-behavior further 
affecting the imaging efficiency, which has been rigorously explored. Mao et al. crosslinked 
small Au NPs (15 nm) to form larger Au clusters (190 nm) via matrix metalloproteinase 
(MMP)-2 cleavable and pH-responsive hydrazone bonds.166 The Au clusters were 
decomposed back to Au NPs within the tumor microenvironment due to the overexpression 
of MMP-2 and acidic environment, and thus showed enhanced tumor penetration and 
contrasting ability in CT imaging. Stimuli-responsive size alteration-induced imaging 
modalities can also facilitate bio-imaging. For example, Lu et al. explored pH-responsive 
iron oxide NPs for MRI imaging.167 Ultrasmall iron oxide NPs (< 4 nm) demonstrated 
enhanced T1 MRI contrast, providing positive contrast (bright signal) on the T1-weighted 
MR images, while larger iron oxide NPs provided negative contrast (dark signal) on the T2-
weighted MR images. The modification of ultrasmall iron oxide NPs with i-Motif DNA, 
which exhibited a pH-triggered structural change, caused aggregation of the iron oxide NPs 
at neutral pH, generating a dark signal, while at the tumor site the aggregates decomposed 
back to ultrasmall iron oxide NPs, generating bright signals. This double-enhancing 
phenomenon can dramatically increase MRI resolution. However, most methods involve a 
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chemical conjugation and reaction, which may bring further obstacles for chemical reagents’ 
removal and quality control Therefore it is preferred to establish an alternative physical 
method to accomplish the envisioned design. 
 
Figure 4. Heterogeneous in vivo microenvironment may bring contradiction for NPs design. On-
demand strategy can endow the system with changeable particle sizes, switchable 
surface charges and activatable/cleavable surfaces, enhancing the imaging capability. 
(A) pH-responsive Au NPs with changeable size showed enhanced CT imaging 
capability comparing to (B) plain Au NPs. (C) and (D) TEM images illustrated the pH 
responsive size change of Au NPs via chemical conjugation. Figures are reprinted with 
the permission from Ref. 166. 
2.2 Advanced materials for DDS fabrication 
The previous sections briefly discussed the design principles for fabricating advanced DDS. 
This section will focus on the selection and modification of specific biomaterials to fulfill 
the envisioned designs. Two types of biomaterials, inorganic (PSi NPs) and organic 
(dextran-based polymer) materials are mainly studied in this thesis and will be separately 
discussed here.  
2.2.1 Porous silicon (PSi) 
PSi was accidentally discovered by the Uhlirs at Bell Labs in 1956, when they were 
searching for a technique to shape the surface of silicon.168 However, it was not  until the 
late 1980s  that the scientific community pursued further interest in PSi, when Dr. Canham 
revealed that PSi could emit light if subjected to electrochemical and chemical dissolution 
due to the quantum confinement effects.169 Along with the increasing investigations for PSi-
based optoelectronic devices, in 1995, Dr. Canham further tested its potential 
biocompatibility with promising results,170 and he later  evaluated PSi as a DDS for the anti-
cancer drug cisplatin.171 As a sequence, a new era was opened for the biomedical 
applications of PSi. The present-day applications of PSi range from bio-imaging, DDS 
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fabrication, sensors and battery anodes for energy storage.13, 17, 172, 173 Herein, we focus on 
the biological applications of PSi. 
2.2.1.1 Biocompatibility and immunomodulatory effect of PSi 
Biocompatibility is a fundamental material characteristic required for biomedical 
applications. Freshly etched PSi with a hydride surface (Si-H) is not fully biocompatible 
due to its high reducibility and the sequential singlet oxygen (1O2) generation as a result of 
photo-oxidation.174, 175 Surface stabilization of PSi can vastly promote the biocompatibility 
of PSi,175 and mainly three types of surface stabilizations have been investigated for the past 
few decades, namely oxidation, carbonization and hydrosilylation (Figure 5).13 Different 
surface chemistry can inevitably alter the PSi surface charge, hydrophobicity, degradation 
rate and biological molecule binding pattern, rendering different interactions between PSi 
and biological systems. 
 
Figure 5. Basic graphic illustration of primary surface modifications for freshly etched PSi. 
Copyright © (2018) John Wiley & Sons, Inc., reprinted with permission from Ref. 13. 
One criterion used to evaluate the biocompatibility of PSi is immunogenicity. 
Understanding the inflammation response of PSi with different surface properties is 
essential for discerning which type of PSi should be administrated to elicit a desired 
biological response. One of the first thorough trials to evaluate the immunogenicity of PSi 
was conducted by Ainsile et al.,176 where human blood-derived monocytes were seeded on 
PSi plates with different topography. Ten key inflammation-related cytokines (interleukin 
(IL)-1α and β, IL-12, IL-6α, tumor necrosis factor (TNF)-α, interferon (IFN)-α and γ, 
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macrophage inflammatory protein (MIP)-1α and β, IL-10 and IL-6) and ROS levels were 
evaluated, respectively. Despite fluctuating cytokines expression with topographically 
different PSi plates, the PSi plate with a nanoporous surface structure showed an overall 
reduced cellular ROS response compared to that with a polystyrene culturing plate. This 
phenomenon could be potently explained by the further work developed by Artzi et al.177 
Within this study, the degradation kinetics of PSi microparticles with a hydrosilylation 
surface was investigated. Surprisingly, the authors found that among all the factors (pH, 
serum, and ROS), ROS concentration exhibited the most important role in determining the 
degradation rate of PSi, which was due to the reductive nature of PSi back bonds. In vivo 
studies further confirmed the elevated PSi degradation rate at a lesion site (tumor) compared 
with healthy tissue. Other reports utilized silicon magnesium nanohybrids to create a 
reductive environment due to the silicon hydride production.178, 179 Considering the critical 
effect of ROS in inflammation regulation, the ROS scavenge effect of PSi may have further 
effects on modulating the inflammation. 
As a result of its heterologous nature, PSi can also directly interact with immune cells, 
rendering immuno-stimulative/suppressive effects. Shahbazi et al. investigated the 
immunomodulatory effect of PSi NPs with different surface chemistries.180 Antigen 
presenting cells (APCs) were used as model cells due to their ability to recognize foreign 
entities and induce immune response via T cell activation by expressing cognate ligands 
(CD80/CD86), and/or releasing cytokines and chemokines to shift inflammation direction. 
Results showed that thermally oxidized PSi (TOPSi) can significantly promote the 
maturation of APCs, which was confirmed by enhanced CD80/CD86 expression and 
elevated pro-inflammatory cytokines excretion. However, thermally carbonized PSi (TCPSi) 
and undecylenic acid functionalized thermally hydrocarbonized PSi (UnTHCPSi) showed 
sparing immuno-stimulation effects, and even inhibited the activation of type 2 T helper 
cells (Th2) to different extents. Similarly, surface oxidized discoidal PSi microparticles, 
despite the altered size and shape compared to spherical PSi NPs, also stimulated the 
secretion of pro-inflammatory IL-1β from murine bone marrow-derived dendritic cells 
(BMDCs) in a time and dose-dependent manner.181 Xia et al. further explained the 
mechanism of this phenomenon as the phagocytosis of PSi might activate Toll-like receptor 
sole adapter molecule (TRIF)-dependent signaling, which elicit type I interferon (IFN-I) 
response in BMDCs.182 Despite the thorough investigations of the immune activation 
processes from surface oxidized PSi, there are only a few papers which can properly explain 
the varied immunogenicity of PSi with different surface chemistries.  
The complexity of the immune system confers a formidable challenge to elucidate the 
effect of a sole factor on immunogenicity. Indeed, previous studies suggested that particle-
induced immune response can be affected by, e.g. particle size, shape and surface 
properties.183-185 Nonetheless, recent studies have suggested that there is a key factor that 
may bridge these factors together. The original NPs’ surface properties will be immediately 
redefined upon being injected into the body due to the protein corona formation, which can 
further prime the immune response of particles. Different protein corona formation can 
regulate the NP/cellular interactions, thus altering the toxicity, targeting ability, bio-
distribution and immunogenicity of the NPs.186-188 Tenzer et al. analyzed time- and NP-
dependent protein corona formation, which shed light on the pathophysiological behavior 
of different NPs.189 A more specific study was developed by Mo et al., who found a 
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decreased immune response from two types of black phosphorous NPs with reduced size.190 
The composition of protein corona was further separated and analyzed via mass 
spectrometry, and the results revealed that only 12.5% of overlapping proteins existed in 
the protein corona composition, and the difference in the protein binding pattern directly 
dictated the immune response. For PSi, Wang et al. previously demonstrated that thermally 
hydrocarbonized PSi (THCPSi) with a dextran coating could reduce immune protein 
(fibrinogen and immunoglobulin G) adsorption compared to bare THCPSi, thus further 
restraining the immuno-stimulation.191 However, the direct in vivo immunogenicity 
comparison of PSi with different surface properties still remains a less investigated topic. 
Moreover, previous studies usually investigated the immunogenicity of NPs on healthy 
animal models, whereas in real cases, particulate DDS will be preferably accumulated in 
lesion sites, and the immuno-modulatory effect of NPs under pre-existing inflammation 
conditions may affect the pathological progression, determining the final treatment 
efficiency. Yet, only few studies have been conducted so far taking into consideration these 
issues.192 
2.2.1.2 PSi for controlled drug release 
Due to the porous structure of PSi, it can be applied for loading various kind of cargos, 
including small molecule drugs, peptides, proteins, DNA, siRNA and even other NPs. 
However, bare PSi shows some inherent drawbacks for DDS fabrication, and therefore need 
further modification. The most common problem is generated by its freely accessible pores 
(~10 nm), which may result in uncontrollable release, and even inactivation of the cargos 
due to the disruptive effect from body fluids when PSi is applied in vivo. Different methods 
have been designed and applied to solve this problem. The simplest and most convenient 
method is adjusting the PSi surface properties to facilitate drug loading and release. 
Hydrophobic interactions can refine the crystalline structure of the drugs and facilitate 
hydrophobic drug loading. Therefore fresh PSi was thermally carbonized to form 
hydrophobic surfaces, which were further applied for loading the hydrophobic anti-cancer 
drug sorafenib.193 Due to the strong hydrophobic interactions, sorafenib cannot be released 
from TCPSi in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer at 
different pH-values, suggesting its potential for long term storage. However, when 10% of 
fetal bovine serum (FBS) was added in the releasing medium, more than 90% of sorafenib 
was released within 1 h, suggesting the limitation of this method when applied in vivo. In 
addition, the physical loading method generally lacks reproducibility and suffers from 
loading efficiency. Thus, advanced methods should be further proposed.23, 193 
Wang et al. leveraged a covalent chemical conjugation method to achieve controlled 
release kinetics from PSi. Amine-terminated thermally carbonized PSi was reacted with the 
anti-cancer drug methotrexate to form an imide bond. A conjugation/loading degree of ~0.4% 
was achieved and a controlled release profile was observed for up to 96 h.194 Despite the 
prolonged release time, mass spectrometry results suggested that the released compound 
was 3-aminopropylesilicic acid conjugated methotrexate, due to the decomposition of PSi. 
Hence, this method induces the concern that changing the chemical structure of the 
compound might disturb the activity of the drug. Thus, an alternative method utilizing 
dynamic non-covalent bonding should be further purposed and investigated. 
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In addition to chemical bonding, physical pore blocking is another commonly applied 
strategy to fulfill the controlled release goal. PSi with hydrosilylation modification 
undertakes moderate degradation within aqueous solution, which will generate orthosilicic 
acid. The degradation product can form in situ into a Ca2SiO4 precipitate in a high calcium 
ion (II) containing medium. The self-limiting precipitation occurs primarily at the PSi 
surface, which consequently forms a shell around the structure. Kang et al. applied this 
method to encapsulate siRNA and a distinctive sustained release profile (> 5 h) was 
achieved. Organic materials can also be applied for PSi encapsulation. THCPSi 
encapsulated in a solid lipid matrix showed an elevated stability and prolonged drug release, 
where the model drug furosemide showed a sustained release behavior for over 10 h.37 Outer 
shell materials can also induce a responsive release profile. For example, the enteric coating 
material hypromellose acetate succinate encapsulated e insulin-loaded PSi, and the 
produced nanohybrids protected the insulin from the stomach’s acidic environment,  while 
releasing the PSi in the intestinal tract.195 Compared to chemical conjugation, physical 
encapsulation has more increased versatility and feasibility, yet a more robust method with 
high throughput production should be proposed. 
2.2.2 Dextran based polymers 
Biodegradable polymeric materials have several inherent advantages, such as flexibility, 
ductility and processability, and thus they have been widely investigated for biomedical 
applications.196 Compared to synthetic polymers, natural polymers are overall more 
biocompatible and biodegradable. Nonetheless there is also a limitation in the performance 
of natural polymers in comparison to synthetic polymers, in regards to mechanical 
properties, thermal stability, shaping efficiency, and stimuli-responsivity.197, 198 Subsequent 
chemical modification may provide natural polymer derivatives some tailored chemical 
functions and structure, and substantially fulfill the unmet requirements mentioned above, 
thus drawing increasing practical interest for further research.199 Dextran, a natural 
polysaccharide with a linear backbone of α-linked d-glucopyranosyl repeating units, is one 
of the few FDA approved natural polymers with favourable aqueous solubility. It can also 
be biodegraded with the assistance from fibroblasts and macrophages without causing 
obvious immuno-responses (Figure 6).200 The abundant hydroxyl groups within the dextran 
units provide feasible reaction sites for chemical modifications, further providing dextran-
based polymers the capability to acquire selectively tailored molecular assemblies and 
interfaces, rendering them more suitable for different biomedical applications. 
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Figure 6. Advantages of dextran for biomedical applications. Adapted and reprinted with the 
permission from Ref. 199. 
One of the first attempts to chemically modify dextran was with periodate induced 
oxidation, where vicinal diols were attacked by a periodate ion and induced carbon bond 
breaking.201 Typical dextran oxidation happens between carbons C3-C4 within the α-1,6 
residues. The attacked C-C bond breaks and yields two aldehyde groups, and the oxidation 
degree can be tuned by altering the periodate concentration.202 This simple procedure 
functionalizes the dextran chain with extra aldehyde groups, which are mainly characterized 
by their highly reactive nature towards N-nucleophiles, such as amines, hydrazines or 
carbazates to form into pH-sensitive (imine) bonds. These oxidized dextran (ODEX) can 
function as a cross-linker to form hydrogels with amine-containing polymers, such as 
chitosan or collagen.203-205 Compared to other commonly used cross-linkers, such as 
glutaraldehyde or genipin, ODEX showed better biocompatibility and a non-inferior 
crosslinking efficiency to enhance the durability and mechanical property of the yielded 
hydrogel.203 Moreover, an amine-containing drug can be concurrently encapsulated in the 
hydrogel to achieve an acid-liable release profile. This pH-responsive release may be 
beneficial for further, specific biomedical applications, such as tissue engineering or cancer 
therapy.92, 206 
Due to the excellent aqueous solubility of dextran, micellization or colloidal preparation 
of dextran into NPs is challenging.207 By grafting hydrophobic functional pendent groups 
on the dextran hydroxyl, one can alter the polymer solubility to facilitate colloidal NPs 
production, and also develop stimuli-responsive polymeric materials based on the chemical 
properties of the pendent groups.26 One example comes from the acetalation of dextran to 
yield the pH-responsive AcDEX. The preparation of AcDEX was first reported by 
Bachelder et al., where 2-methoxypropene was used to modify dextran.94 Sufficient 
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hydroxyl substitution by ketal/acetal groups makes AcDEX insoluble in water, but soluble 
in multiple organic solvents. This hydrophobicity alteration allows AcDEX NPs synthesis 
via facile methods, such as emulsion or precipitation. Attributed to the acid-liable nature of 
acetal/ketal bonds, AcDEX will undertake fast degradation under pH 6, generating water-
soluble dextran, methanol, and acetone as degradation product. This pH-responsive 
degradation makes it a perfect candidate for constructing a series of pH-responsive on-
demand DDS. The structure changes or degradation of the modified hydrophobic pendants 
on the hydroxyl groups can also result in different on-demand behavior. Broaders et al. 
conjugated phenylboronic acid ester (PAE) onto dextran to yield an oxidation responsive 
polymer (Oxi-DEX). Due to the sensitivity of PAE towards H2O2, Oxi-DEX degraded back 
to water-soluble DEX and borate upon the addition of H2O2, and is thus capable of being 
applied to the fabrication of oxidation-responsive on-demand DDS.208 Despite the 
successful application in constructing DDS for vaccine delivery, this polymer can only 
respond to H2O2, but not to other ROS species, and the effective degradation can only be 
initiated at relatively high H2O2 concentration (1 mM), which is barely achieved within the 
extracellular environment.115, 131 In addition, boronic acid may form a transient crosslink 
with vicinal diols in dextran, and thus restrain the solubility of Oxi-DEX in most of the 
solutions. The addition of methanol can partially resolve the solubility impediments, but it 
may induce methanolysis, which might be detrimental for the NPs fabrication.  
Overall, despite the obvious advantages of applying dextran as a precursor backbone 
polymer, an elaborative pendent choice should be further considered to achieve the 
envisioned design for fabricating the functional polymers. 
2.3 Microfluidics for NPs preparation 
As mentioned above, the on-demand strategy brought up the proof of concept to fabricate 
corresponding DDS for responsive/controlled release of loaded drugs, as well as 
synchronously exerting extra functions, such as cellular imaging, drug release monitoring 
and bio-imaging facilitated theranostics. However, the envisioned design needs cutting-
edge techniques to accomplish the NPs fabrication. In recent years, the concept “Lab on a 
Chip” dramatically accelerated the development of miniaturized systems for healthcare 
related applications.209 As a fundamental regime, microfluidics, a technology characterized 
by the engineered manipulation of fluids at the submillimeter scale, has become a 
revolutionary alternative method in the biomedical field.210 It has been widely applied in 3D 
cell cultures, single cell analysis, cell/molecule isolation and purification, body fluidic 
stream simulation, organ on chip, micro/nano-fibers production and micro/nano-particles 
production.38, 41, 211 From a pharmaceutical point of view, certain advantageous properties 
of applying microfluidics technology to fabricate micro/nano-sized particles, such as rapid 
and controllable processing with favourable reproducibility, have made it an attractive 
candidate to replace traditional approaches for producing NPs or microparticles. The 
following sections will briefly discuss recent technologies that applied microfluidics to 
fabricate advanced DDS, and the potential formation mechanisms. 
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2.3.1 Microfluidic-assisted production of NPs 
The initial and most widely applied particulate synthesis via microfluidics is for 
microparticles production. However, the focus here will be mainly on NPs’ fabrication. NPs 
are conventionally synthesized by batch type reactors, where the scarcity of batch-to-batch 
reproducibility for bulk-method is usually a refractory obstacle for quality-control. Figure 
7A-C briefly illustrates the basic method for microfluidic-assisted NPs production. Using 
microfluidics, the continuous synthesis of NPs was found to obtain better reproducibility 
and controllability compared to batch-type bulk synthesis methods.212 This is mainly due to 
the unique fluid dynamics in microfluidic systems. 
Most of the bottom-up NPs formation undertakes two phases, a nucleation phase and 
growth phase.213-215 Theoretically, the NPs precursor (fully dissolved lipid or polymers for 
organic NPs and ions or ions/ligand complex for inorganic NPs) will be evenly distributed 
within a homogenized solution. Upon the addition of an initiator (anti-solvents for organic 
NPs and reacting agent for inorganic NPs), the precipitation or reaction is initiated and forms 
into NPs (Figure 7D). The successful synthesis of monodisperse NPs is critically dependent 
on the complete separation of the nucleation and growth stages, which requires precise 
control over the concentration of reagents, reaction temperature and reaction time.213 
However, in most cases, the reaction or precipitation usually happens in a heterogeneous 
environment due to the detained mass or heat transfer, leading to uneven mixing, local 
temperature fluctuations and uncontrolled reaction times,216 thus resulting in relatively high 
polydispersity and batch-to-batch variation. For example, the most commonly used method 
for fabricating polymeric NPs is anti-solvent induced precipitation or self-assembly. The 
counterbalance between the time scale for thorough mixing of the anti-solvent (tmix) and the 
time scale for polymer nucleation (tnul) directly determines the successful construction of 
the NPs. Only when tmix < tnul, can the nucleation occur in a homogenized environment, and 
effectively prevent the secondary nucleation due to non-homogenous local polymer 
concentration.217, 218 Therefore, one pivotal factor to construct NPs with good 
reproducibility and monodispersity is to increase the mixing efficiency. Microfluidics can 
widely increase in surface area-to-volume ratio by even several orders of magnitude.42 For 
a system containing two or more phases of miscible fluids, which is mainly used in 
microfluidic-assisted NPs production, the widely enhanced surface area-to-volume ratio 
allows for more efficient mass or heat transfer within the system; This reduces the 
homogenization time to micro-second levels,212, 219 and provides a new era for fabricating 
NPs via bottom-up methods. 
The typical method for microfluidic-assisted NPs’ production is by introducing two or 
more coaxial flows, which separately contain precursors and initiators. The NPs will 
spontaneously form upon the mixing of the co-flows within the channels (Figure 7A-C). 
Diffusion and convection are the two regimes commonly used in microfluidics that 
contribute to the mixing efficiency. Diffusion refers to the random motion of solutes driven 
by a gradient in chemical potential and convection refers to the mixing caused by the 
convective motion of fluids.220 When discussing about mass transfer, one parameter is 
inevitably to be introduced for further discussion. The Peclect number (Pe) describes the 
ratio between characteristic time of diffusive mixing and characteristic time of convective 
mixing, where higher Pe indicates a more important role of convective bulk flow within the 
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mixing.221 Based on the equation, Pe = 𝑉𝐷 𝑑⁄ , where V is the total flow speed within the 
microfluidics channel, D is the hydraulic cross-sectional diameter of the channel and d is 
the mass diffusion coefficient of the solute. For a typical sub-millimeter sized microfluidic 
channel (with the a diameter less than 10-3 m), two miscible fluids (such as ethanol and 
water, which is one of the most commonly used fluidic systems for fabricating polymeric 
NPs) usually obtain a typical Pe number ranging from 102 to 104,222 suggesting the main 
function of convection flow during the mixing. Given the knowledge that the extent of 
convection is mainly dominated by the fluidic pattern in the microfluidics channel, to better 
understand and control the mixing, another important dimensionless parameter is introduced, 
namely Reynolds number (Re). Re, defined as Re =  
𝜌𝑄
𝜂𝐷⁄  = 
𝑄
𝜈𝐷⁄ , where ρ is the density 
of the fluid, Q is the total flow rate of the fluid, η is the viscosity of the fluid, ν is kinematic 
viscosity of the fluid and D is the hydraulic diameter of the channel, reflects the ratio of 
inertial to viscous force within the fluid.220 Because viscosity produces a resistance to shear 
and the fluids have a tendency to move in parallel layers, the increase in Re suggests a more 
chaotic and stochastic fluidic pattern, ultimately resulting in a shift from laminar to turbulent 
flow. Despite the difficulty in predicting and modeling fluid mechanics in turbulent flow, 
the mixing efficiency within the turbulent regime is enhanced since convective mixing does 
not occur in laminar flow and is therefore preferred for NPs synthesis. 
Therefore, one method to increase the mixing efficiency is by promoting the Re number. 
Based on this theory, Farokhzad et al. used a co-axial microfluidics device to synthesize a 
series of NPs, ranging from polymeric NPs (PLGA-PEG, polystyrene), liposomes to metal 
nanoclusters (iron oxides) via the nanoprecipitation method. Re was varied by tuning the 
total flow rate and flow velocity ratio between the inner and outer fluids (Rin/out). Under a 
fixed Rin/out value, with the increase of Re, a clear flow pattern change from laminar flow to 
vortex and turbulence flow, and ultimately to turbulent jetting, was observed (Figure 7E). 
It should be noted that the conventional transitional Re number (Ret), which refers to the 
critical Re number when the flow pattern shifts from laminar flow to turbulent flow, is 
usually observed at around 2000 to 2300. However, in microfluidics, a clear turbulent flow 
can be achieved with a Re number lower than 500.223 Peng et al. first reported that the 
transition to turbulence occurred at  Re numbers as low as 200–700 in micro-channels with 
hydraulic diameters of 133–367 μm,224, and a similar phenomenon was observed by Mala 
et al. and other groups.225 They attributed this phenomenon to the decreased diameter and 
increased surface roughness of the channel. In a comprehensive review illustrating the 
calculation of Re in a microfluidics system, Gravesen et al. claimed that Ret in a 
microfluidics system should be consider the channel length.223 Despite the controversial 
conclusion about the Ret within microfluidics channel and corresponding flow pattern,
226 
Farokhzad et al. clearly demonstrated that by simply manipulating Re number, one can 
fabricate NPs with significantly enhanced homogeneity comparing to bulk method.227 To 
further illustrate the mechanism, they evaluated the tmix through both by macroscopic 
observations and mathematical modeling. Results showed that the tmix was tunable in the 
range of 7–53 ms by changing the Re, which was considerably lower than the typical tnul of 
polymer (∼1–100 ms, depending on the molecular weight of the chain, Figure 7F).212, 217 
Liu et al. further applied a computational fluidic dynamics (CFD) method to confirm the 
amplified microvortices in the microfluidics channel along with the increase of Re (Figure 
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7G), confirming the evaluated mixing efficiency and NPs homogenicity by increasing the 
Re number (Figure 7H).228 
 
Figure 7. (A-C) Representative illustration of typical microfluidic chip structures for conducting 
co-flow nanoprecipitation. (D) Brief illustration of NPs formation starting from (I) well 
dispersion of the precursor to (II) nucleation and (III) growth, suggesting the 
significance of fast mixing in producing monodisperse NPs. (E) Graphic and 
macroscopic illustration of flow pattern transfer with increasing Re. (F) The mixing 
time can be decreased to milliseconds as Re increases; (G) CFD simulation of 
enhanced mixing vortex along with increased Re. (H) Production of PLGA NPs by 
microfluidics showed better polydispersity than the bulk method. (I) Enhancing mixing 
efficiency at low Re by fabricating complex geometry, such as a herringbone structure. 
Figure B is reprinted with the permission from Ref. 229, Figure C is reprinted with the 
permission from Ref. 230, Figure D is reprinted with the permission from Ref. 217, Figure 
E-F is reprinted with the permission from Ref. 227, Figure G-H is reprinted with the 
permission from Ref. 228, Figure I is reprinted with the permission from Ref. 231.  
Manipulating Re number in order to enhance the mixing efficiency, it usually needs 
extra high flow rate to achieve the desired effect, which may be constrained by the 
maximum force of the fluidic pumps. The other commonly used method is typically based 
upon smart design of channel geometries.232 One typical example leveraging this strategy is 
to prepare nano-liposomes. Complex geometry can decrease the mixing length at relatively 
low Re, thus increasing the polydispersity of the liposomes as discussed previously, and 
also ascertaining to obtain uni-lameller vesicles by preventing the lipid bi-layers stacking 
during the hydration process.233, 234 Various types of microfluidic chips with complex 
geometry, such as Tesla-shape, herringbone-shaped, serpentine-shaped and zigzag-shaped 
channel, were designed and applied for preparing liposomes.235-237 For example, 
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herringbone-shaped microchannel containing patterned microgrooves of varying shapes and 
angles can induce chaotic stirring at a low Re (Re = 10-2102) (Figure 7I).231 Previous studies 
demonstrated that tmix can reduced to ~8 ms at relatively low total flow rate (600 μL/min) by 
applying this apparatus.238 However, to fabricate complex geometry, the most commonly 
used material for preparing the microfluidic chips is polydimethylsiloxane (PDMS), 
whereas PDMS is not resistant to many organic solvents, which may constrain its potential 
application for producing NPs.239 
2.3.2 Microfluidic-assisted production of nanohybrids 
Recently, there has been more focus on the incorporating two or more nanomaterials, 
namely nanohybrids, to achieve increased multifunctionality and create opportunities for 
the next generation of materials with enhanced in biocompatibility, stability and drug release 
control.240 Various nanohybrids with core/shell structures, such as organic/inorganic 
nanohybrids, inorganic/inorganic nanohybrids and lipid/polymer nanohybrids have been 
designed and synthesized for DDS fabrication.37, 241, 242 The conventional two-step method 
of separately preparing the core structure and the sequential shell coating usually has poor 
control over the encapsulation efficiency and reproducibility. With the development of 
microfluidics, a one-step method combining the simultaneous nanoprecipitation of core NPs 
and shell coating show considerable advantages by reducing intermediate disturbances and 
batch-to-batch variation.243 
One of the first trials with potential mechanical explanations was proposed by Karnik et 
al.243 The aim of the experiment was to fabricate lipid/polymer nanohybrids with PLGA 
NPs core and lipid outer layers through a microfluidic-assisted single step encapsulation. A 
co-flow, flow-focusing microfluidic chip was applied with PLGA in acetonitrile as the inner 
phase and lipid in EtOH/water as the outer phase. They found that this single step 
nanoprecipitation could form nano-sized (~40 nm) PLGA/lipid core/shell structures. 
Interestingly, the size of the newly formed nanohybrid was smaller than both bare PLGA 
and bare liposomes under the same synthesis conditions. They proposed that this 
phenomenon was due to the fast dispersion of lipid molecules within the mixing medium, 
rendering the coverage of lipid at the surface of the PLGA core, while the exposed 
hydrophilic part of lipid further arrested the growth of PLGA NPs. This generated the final 
nanohybrids with an overall reduced size compared to blank PLGA NPs. A corresponding 
mathematical simulation and calculation were introduced to prove the hypothesis, and the 
results showed that the time scale for total homogenization of the medium was around 0.23 
ms, at least one an order of magnitude faster than the timescale for PLGA nucleation, 
suggesting the PLGA nucleation was initiated under a homogenized condition. On the other 
hand, the time scales of diffusion and binding between lipid and PLGA nucleates were on 
the same order as PLGA nucleation, indicating the simultaneous lipid coating at the PLGA 
surface. 
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Figure 8. (A) Schematic illustration of PLGA@Lipid core/shell structure synthesis. (B) 
Molecular dynamics simulation of the encapsulation process. (C) Graphic illustration 
of Fe2O3@SiO2 nanohybrid fabrication. (D) Graphic illustration of 
inorganic@organic core/shell nanohybrids fabrication and the representative 
transmission electron microscopy (TEM) image of PSi NPs before (E) and after (F) 
encapsulation. Figures A-B are reprinted with the permission from Ref. 244. Figure C 
is reprinted with the permission from Ref. 245. Figure D-F are reprinted with the 
permission from Ref. 96. 
This “core nucleation-surface stabilization-shell formation” concept may further be 
applied to controlled drug loading and release if the “core” is composed of drug nano-
crystals. Liu et al. developed a microfluidics platform with two consecutive precipitation 
processes, where the first step precipitation produced drug nano-crystals with fully 
dissolved polymer, which was precipitated out and coated the drug nano-crystals to form 
core/shell structures. More specifically, the application of this platform increased the 
paclitaxel (PTX) loading degree from ∼6.7% to 42.6% and sorafenib (SFN) loading degree 
from 6.2% to 45.2%.246 More recently, Prud’homme et al., guided by the aforementioned 
hypothesis of the core/shell formation process, established a mathematical model with the 
equation R = [𝐾 (
𝑘𝐵𝑇𝑐𝑐𝑜𝑟𝑒
5
3⁄
𝜋𝜇𝜌𝑐𝐵𝐶𝑃
)]
1
3⁄
, where R is the predicted average aggregate radius for the 
final nanohybrids, T is the absolute temperature, kB is the Boltzmann constant, μ is the 
solvent viscosity, ρ is the bulk density of the core, and ccore is the mass concentration of the 
core material during particle assembly (one-half of the concentration at the beginning), cBCP 
is the mass concentration of the shell material during particle assembly (one-half of the 
concentration at the beginning) and K is a single scaling constant with the value 253 
ms·g1/3/m.247 This newly established equation was based on the assumption that the time at 
which particle growth was halted, tf, was inversely proportional to the surface area of the 
core structure (proportional to ccore
2/3) and the surface area of the shell structure 
(proportional to cBCP). To confirm this theory, a series of nanohybrids with hydrophilic 
stabilizer (PEG) containing co-polymer coatings were feasibly fabricated. The yielded size 
of the nanohybrids matched the size obtained from the equation above, therefore the 
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importance of this equation is to predict the required formulation composition with a given 
hydrophobic compound. However, it should be noted that the key parameter within the 
equation, K, was rather an empirical number obtained from the actual experimental data and 
the successful prediction may likely be dependent on the stabilizing polymer used. Despite 
that, considering the most commonly used stabilizer within this study (PEG), this simple 
and user-friendly equation may show particular significance in biomedical nanohybrids 
fabrication. 
Despite one-step synthesis of organic core/shell nanohybrids, microfluidics can also 
encapsulate pre-existing NPs to form core/shell nanohybrids. Jiang et al. dispersed as-
prepared nano-liposomes (40 nm) in aqueous solution as anti-solvent, which precipitated 
PLGA dissolved in N,N-dimethylformamide (DMF) solution, to prepare PLGA NPs 
encapsulated nano-liposomes (Figure 8A). Computational molecular dynamics simulation 
was further established to illustrate the encapsulation process (Figure 8B).244 Not only 
organic NPs, but various inorganic NPs based DDS were also applied to this method to 
increase the inherent biocompatibility and stability. Cabuil et al. established a multi-step 
continuous synthesis method for fabricating iron oxide@silica core/shell nanohybrids.245 
The (3-aminopropyl)-triethoxysilane (APTES) grafted Fe2O3 NPs were co-mixed with 
tetraethyl orthosilicate (TEOS) in the channel to deposit silica shell on the surface of Fe2O3 
(Figure 8C). Valencia et al. provided a facile method to encapsulate quantum dots (QDs, 
~5 nm) within lipid matrix by dispersing QDs in organic solution, the flow was further 
focused by lipid aqueous solution. The generated nanohybrids showed an overall enhanced 
hydrophilicity, stability in plasma, and an overall improvement in their biocompatibility.243 
Despite smaller metal clusters, such as iron oxide and Au NPs, which usually obtained the 
size below 10 nm, larger inorganic NPs (~200 nm) such as PSi NPs or copper NPs could 
also be encapsulated within the polymer matrix. Upon the mixture with the anti-solvent, the 
precipitation of the polymer was preferably initiated at the surface of inorganic NPs, thus 
encapsulating the template inorganic NPs (Figure 8D-F).96, 248 Corresponding potential 
mathematical calculations were also established by Gindy et al.249 Within the study, 
Smoluchowski diffusion-limited growth kinetics were used to characterize the 
encapsulation of Au NPs into the polymeric nanoparticles. The given equation, [𝑃𝑁] 
=[𝑃0
𝑡𝑜𝑡] (
𝑡
𝜏
)N-1(
𝑡
𝜏
)-N-1, characterizes how the number concentration of produced nanohybrids 
in solution, PN, at a settled concentration of shell polymer , 𝑃0
𝑡𝑜𝑡 , changes over time, t. 
Considering PN can reflect the size of the nanohybrids, the main function of the equation is 
to predict the size of the produced nanohybrids, whereas another fundamental question, 
regarding the parameters determining successful encapsulation of the core NPs, has been 
less investigated. As in most cases, the selected shell materials may not effectively 
encapsulate the core NPs. In addition, to achieve further multi-functionalities, simultaneous 
co-encapsulation of two or more types of NPs with altered physiochemical properties within 
one polymer matrix is also in great demand, yet few papers have demonstrated a single-step 
co-encapsulation of different NPs at the same time. 
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3 Aims of the study 
A cutting-edge DDS should be capable of recognizing and responding to specific biological 
microenvironments in a dynamic way, simultaneously releasing the loaded cargo in a 
controlled manner, and preferably having a synchronous bio-imaging ability with multi-
functionalities. This can substantially emphasize the advantages of nanotechnologies and 
facilitate personalized treatment. Taking advantage of the high capacity of PSi for the 
loading of both hydrophilic and hydrophobic active compounds, the aim of this dissertation 
was to develop a series of on-demand PSi based nano-sized DDS for different biomedical 
applications. Biocompatibility, especially immunogenicity of PSi with different surface 
chemistry at pre-existing lesion sites were also investigated to better evaluate the feasibility 
of DDS for clinical use. 
The specific objectives of this dissertation were as follows: 
1. To fabricate a DOX-loaded DDS with a pH-responsive releasing profile. A 
dopamine-inspired ligand was synthesized and functionalized PSi, and the 
drug release was monitored by fluorescence imaging (I). 
2. To fabricate a PSi-based DDS which would specifically target CA IX over-
expressing cancer cells. The pH-responsive DOX release was monitored by 
FRET (II). 
3. To fabricate multi-components, multi-functional pH-responsive polymer 
shell-PSi/Au NPs core nanohybrids by a single-step microfluidics method. 
Simultaneous encapsulated hydrophobic drug was applied for liver 
regeneration. Co-resided Au NPs could enhance CT contrasting abilities, thus 
facilitating liver failure theranostics (III). 
4. To fabricate a self-regulated nanohybrid with PSi core and polymer matrix 
outer layer via a single-step microfluidics method with 
hydrophilic/hydrophobic dual-drugs loading. The development of a close-loop 
DDS for recapitulated hyperglycemic condition with regulated drug release 
and facilitated stage-specific diabetic wound healing (IV). 
5. To investigate the immunogenicity and biological effect of PSi with different 
surface chemistries under pathological condition, and to further propose the 
potential mechanism for the phenomenon (V). 
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4 Experimental 
Detailed description of the methods, suppliers of the materials and the equipment used in 
this thesis can be found in the respective original publications (I–V). The PSi nanoparticles 
were produced by collaborators at the Laboratory of Industrial Physics, Department of 
Physics and Astronomy at the University of Turku, Finland. 
4.1 Fabrication of the drug delivery carriers 
4.1.1 Fabrication of PSi nanoparticles (I–V) 
The PSi particles were produced by electrochemical etching of monocrystalline boron–
doped p+ type Si 100 wafers (Cemat Silicon S.A., Poland) with a resistivity of 0.01–0.02 
Ω.cm in a 1:1 (v/v) aqueous hydrofluoric acid (38%)–EtOH electrolyte with a current 
density of 50 mA/cm2 in the dark, as described elsewhere.173 The porous layer was detached 
from the substrate as a film by increasing the current density to the electro-polishing regime.  
For the PSi nanoparticles in publications I–IV, thermally hydrocarbonized PSi (THC) 
films were obtained by heating at 500 °C under 1:1 N2-acetylene flow for 15 min. 
undecylenic acid-terminated THCPSi (Un) films were obtained by treating THCPSi films 
in undecylenic acid at 120 °C for 16 h to obtain terminated carboxylic acid films, adapting 
the thermal addition process described elsewhere.250 Next, the Un NPs were prepared by 
wet-milling in undecylenic acid and then centrifuged to obtain the required PSi NP size.173, 
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For the PSi nanoparticles in publication V, Un NPs were obtained with the same protocol 
as described before. Thermally carbonized (TC) PSi films were obtained by heating the 
THCPSi films absorbed with acetylene at 820 °C for 10 min.252 Wet ball milling was carried 
out in 1-decene to reduce the size of the TC PSi multilayer films. Thermal oxidized PSi (TO) 
was made by exposing the fresh films to ambient air for 2 h at 300 °C, and the NPs were 
produced by wet ball milling the TO multilayer films in EtOH.96 After milling, the excess 
silane was removed by replacing the liquid and redispersing the NPs in fresh toluene and 
EtOH for at least three times using centrifugation. The size sorting and change of the 
suspension media was achieved by centrifugation of the Un, TC and TO PSi NPs. The final 
NPs were dispersed in EtOH.  
4.1.2 Fabrication of multifunctional pH-responsive nanocomposites (I) 
Firstly, inspired by the structure of dopamine, a derivative of natural flavone quercetin, 
namely 3-aminopropoxy-linked quercetin (AmQu), was synthesized and the detailed 
synthetic route can be found in publication I. Afterwards, 1 mg of the as-prepared Un NPs 
were dispersed in 1 mL of anhydrous N,N-dimethylformamide (DMF). After the addition 
of 8 μL of N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) and 6 
mg of N-hydroxysuccinimide (NHS), the solution was stirred overnight. Then 5 mg of 
AmQu was dissolved in 1 mL of anhydrous DMF and mixed with the solution to react for 
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24 h. The AmQu-UnTHCPSi was thoroughly washed three times with DMF to remove the 
electrostatically adsorbed AmQu, and then stored for further use. AmQu-UnTHCPSi NPs 
containing 1 mg of UnTHCPSi were then re-dispersed in 2 mL of ethanol, followed by the 
addition of 1.43 mg of Fe(NO3)3•9H2O. The resulting mixture was stirred for 24 h. Finally, 
the Fe3+-AmQu-UnTHCPSi (FAP) particles were centrifuged, washed three times with 
EtOH, and dispersed in EtOH for subsequent usage. 
4.1.3 Fabrication of multifunctional hypoxia-targeting nanocomposites (II) 
Initially, a specific carbonic anhydrase IX (CA IX) targeting ligand VD11-4-2 was 
synthesized for further modification.253 Un NPs (1 mg) were dispersed in anhydrous DMF 
(1 mL). EDC (8 μL) and NHS (6 mg) were added in the solution and stirred for 2 h. Then, 
5 mg of NH2-PEG-NH-tert-butyloxycarbonyl (Boc, Iris Biotech, Germany) was dissolved 
in 1 mL of anhydrous DMF and mixed with the solution to react for 24 h. The Boc-NH-
PEG-Un was thoroughly washed three times with DMF and then redispersed in 3 mL of 
CH2Cl2 (DCM) containing 1.8 mL of trifluoroacetic acid (TFA). The solution was stirred 
for 3 h to remove the Boc protection. Then NH2-PEG-Un particles were washed with 
saturated NaHCO3, dd-H2O, EtOH, and DCM, once with each, and finally redispersed in 1 
mL of toluene. Dry toluene (2 mL), VD11-4-2 (1 mg), and N,N'-Carbonyldiimidazole (CDI, 
0.4 mg) were added to a 10 mL round-bottom flask fitted with a dry argon (Ar) inlet and 
magnetic stirrer and heated to 60 °C with stirring for 3 h. The as-prepared NH2-PEG-Un 
was then added drop-wise. The solution was left to stir at 60 °C overnight to obtain the final 
VD11-4-2-PEG-Un (further described as VD-PSi). Particles were washed three times with 
ethanol and stored in ethanol for further usage. 
4.1.4 Fabrication of microfluidic flow–focusing device (III–IV) 
Microfluidic flow-focusing devices were fabricated by assembling borosilicate glass 
capillaries on a glass slide (publications III and IV). One end of the cylindrical capillary 
(World Precision Instruments, Inc.), with inner and outer diameters of around 580 and 1000 
µm, respectively, was tapered using a micropipette puller (P-97, Sutter Instrument Co., USA) 
to a diameter of 20 m; this diameter was further enlarged to ca. 80 µm using a sand paper. 
This cylindrical tapered capillary was inserted into the left end of the cylinder capillary with 
inner dimension of around 1100 µm (Vitrocom, USA), and then coaxially aligned. A 
transparent epoxy resin (5 Minute Epoxi, Devcon) was used to seal the capillaries. Two 
immiscible liquids were injected separately into the microfluidic device through 
polyethylene tubes attached to syringes at selected flow rates with constant flow. The flow 
rate of the different liquids was controlled by syringe pumps (PHD 2000, Harvard Apparatus, 
USA). 
4.1.5 Fabrication of pH-responsive PSi/ Au nanohybrids (III) 
pH-responsive biocompatible polymers AcDEX and spermine AcDEX were prepared by 
reversibly modifying dextran with acetal–protecting groups, as described in publication III. 
To achieve single-step co-encapsulation of different NPs simultaneously, prior to the 
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encapsulation, both PSi and Au NPs were modified to alter the surface properties. The Au 
NPs were initially synthesized with dodecanethiols as the capping monolayer (Nanoprobe, 
USA). To further conjugate the Au NPs onto spermine AcDEX, the Murray place exchange 
method was carried out to functionalize the Au NPs with a desired ligand. Briefly, 2 mg of 
Au NPs were mixed with a solution of 20 μL of 3-mercaptopropionic acid and 1 mL of TEA 
in EtOH. The mixture was stirred under argon at room temperature for 4 h and was then 
dried under vacuum. The black precipitation was further re-dispersed in DMF. Next, as-
prepared Au-COOH was added in 12 mg of NHS and 16 μL of EDC. After stirring for 1 h, 
100 mg spermine AcDEX was subsequently added and left to react overnight.  The reaction 
was terminated by adding 4 mL of dd-water and the product was collected by centrifugation, 
and washed by EtOH 3 times. The spermine AcDEX modified Au NPs (DAu) solution was 
redispersed in EtOH for further use. 1 mg of the as-prepared Un NPs were dispersed in 1 
mL of anhydrous DMF. After the addition of 8 μL of EDC and 6 mg of NHS, the solution 
was stirred overnight. Then 50 mg of as-prepared spermine AcDEX was dissolved in 1 mL 
of anhydrous DMF and mixed with the solution to react overnight. The spermine AcDEX 
modified Un NPs (DPSi) were thoroughly washed three times with EtOH to remove the 
electrostatically adsorbed spermine AcDEX, and then stored for further use. For the 
preparation of DPSi, DAu encapsulated nanohybrids (DPSi/DAu@AcDEX), a microfluidic 
3D co-flow focusing glass capillary device was used at room temperature. DPSi (0.5 
mg/mL), DAu (2.5 mg/mL) were dispersed into the AcDEX (10 mg/mL) EtOH/acetonitrile 
(90:10, v/v, with 0.2% TEA) co-solvent solution with a desired concentration, which 
together served as the inner fluid; the outer fluid was composed of 1% Poloxamer-188 (P-
188) solution. The inner (1 mL/h) and outer (20 mL/h) fluids were separately pumped into 
the microfluidic device, in which the inner fluid was focused by the continuous outer fluid. 
In this procedure, water insoluble AcDEX self-assembled into the nanocarriers during 
diffusion from the organic solution into water, and thus, the nanohybrids 
(DPSi/DAu@AcDEX) were obtained. 
4.1.6 Fabrication of close-loop nanohybrids loaded with collagen ark (IV) 
A phenylboronic acid ester (PAE) containing oxidative responsive polymer (POD) was first 
synthesized by conjugating 4-(hydroxymethyl)-phenylboronic acid pinacol ester on 
oxidized dextran, where dextran was oxidized with sodium periodate. The detailed synthesis 
routine can be found in publication IV. POD cannot fully dissolve in the preferred solvent. 
Therefore, prior to the experiment we dispersed 30 mg of POD in 1 mL of EtOH/H2O co-
solvent (80/20, v/v). After bath sonicating for 10 min, the sample was centrifuged and the 
supernatant with a POD concentration of 15 mg/mL was collected. For the preparation of 
PSi encapsulated nanohybrids (PSi@POD), a microfluidic 3D co-flow focusing glass 
capillary device was used at room temperature. PSi (1 mg/mL) was dispersed into the POD 
(15 mg/mL) EtOH/H2O (80/20, v/v) co-solvent solution with a desired concentration, which 
served as the inner fluid; the outer fluid was composed of dd-H2O (pH = 7.2). The inner (1 
mL/h) and outer (10 mL/h) fluids were separately pumped into the microfluidic device, in 
which the inner fluid was focused by the outer continuous fluid. In this procedure, water 
insoluble POD self-assembled into the nanocarriers during diffusion from the organic 
solution into water, and thus, the nanohybrids (PSi@POD) were obtained. Afterwards, 10 
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μg of GOx was added in 10 mL of as-prepared PSi@POD solution and stirred overnight to 
initiate the Schiff-base facilitated protein conjugation, resulting in the production of close-
loop glucose responsive nanohybrids. The as-prepared nanohybrids were then embedded on 
a water-insoluble collagen patch with the diameter of 1 cm × 1 cm × 0.4 cm (l/w/h) to obtain 
the final nanohybrids/patch composites. 
4.1.7 Dual-drug loading for different nanoparticles (I–IV) 
For PSi-based NPs in publication I, a certain amount of Fe3+-AmQu-UnTHCPSi (FAD) 
containing 100 μg of Un was mixed with 200 μg of DOX in 1.0 mL of PBS (pH 7.4), and 
stirred at room temperature overnight. The mixture was centrifuged and washed three times 
with 6.7 mM PBS (pH 7.4). 
For PSi-based NPs in publication II, a certain amount of VD-PSi and PSi particles 
containing 1 mg of PSi was dispersed into 2 mL of PBS buffer at pH-value  7.4, and then 3 
mg of DOX was added and stirred overnight. After the drug loading, the particles were 
collected by centrifugation and prepared for further studies. 
For PSi-based nanohybrids in publication III, prior to the microfluidics assisted 
nanoprecipitation, 1 mg of DPSi was immersed in 0.5 mL of a dimethyl sulfoxide (DMSO) 
solution containing the hydrophobic drug XMU-MP-1 at a concentration of 50 mg/mL. 
Then, the particles were collected by centrifugation and washed with dd-H2O for three times 
and re-dispersed into AcDEX solution for further encapsulation. 
For PSi-based nanohybrids in publication IV, both hydrophobic (atorvastatin, ATO) and 
hydrophilic (deferoxamine, DFO) drugs were loaded in the nanohybrids. For ATO loaded 
nanohybrids, 4 mg/mL of PSi was mixed with 20 mg/mL of ATO methanol solution 
overnight The ATO-loaded particles were then collected through centrifuge and the residual 
methanol on the particle surface was gently washed away with dd-H2O. Afterwards the 
drug-loaded PSi were dispersed in POD solution at corresponding concentrations and 
encapsulated by microfluidic-assisted nanoprecipitation, as described previously. To 
construct DFO, ATO dual-drug loaded nanohybrids, 100 μg of DFO and 10 μg of GOx were 
added in 10 mL of as-prepared ATO-encapsulated PSi@POD solution and stirred overnight 
to initiate the Schiff-base facilitated drug conjugation. 
4.2 Characterization of the fabricated carriers 
4.2.1 Physiochemical characterization of the nanoparticles (I–V) 
The porous properties of the PSi particles were studied using N2 adsorption/desorption 
(publications I–V). The surface area and pore characteristics of the particles were 
determined by Brunauer–Emmet–Teller and Barret–Joyner–Halenda theories.254 
The chemical structures of the synthesized small molecules or polymers were confirmed 
by 1H NMR (publications I–IV) or 13C NMR (I) (AVANCE III, Bruker, Switzerland). The 
H2O2 dependent polymer degradation (publication IV) was confirmed by 
1H NMR. 
Nanoparticle size measurements (publications I–V) were performed using DLS with 
Zetasizer NanoZS (Malvern Instruments Ltd., UK). For each measurement, the sample was 
loaded in a disposable polystyrene cuvette (SARSTEDT AG & Co., Germany). The 
31 
 
nanocarrier surface zeta-potential (ζ-potential) was measured with Zetasizer NanoZS using 
disposable folded capillary cells (DTS1070, Malvern, UK). Particle stability in human 
plasma (publication II) was investigated by incubating the NPs with human plasma at 37 °C 
for 2 h. Samples were withdrawn at different time intervals and diluted several times with 
water before measuring the average particle size and ζ-potential (Zetasizer Nano ZS, 
Malvern Instruments, UK). Anonymous donor human plasma was obtained from the 
Finnish Red Cross Blood Service. 
The structures of the fabricated nanocarriers (publications I–V) and the glucose 
dependent particle degradation (publication IV) were evaluated by transmission electron 
microscopy (TEM, Tecnai 12, FEI Company, USA) at an acceleration voltage of 80 kV. 
The TEM samples were prepared by depositing 2 µL of the nanocarrier suspension with 
proper concentrations onto carbon-coated copper grids (300 mesh; Electron Microscopy 
Sciences, USA). 
The morphology and surface topography of the nanohybrids/patch composites 
(Publication IV) were evaluated by SEM. The images were taken using a Hitachi S-4800 
(SEM, Hitachi, Japan). 
The qualitative analysis of the surface modification and interaction (publications I–IV) 
of the NPs were determined by Fourier transform infrared spectroscopy (FTIR) with a 
Vertex 70 spectrometer (Bruker Optics, USA), using a horizontal attenuated total 
reflectance (ATR) accessory (MIRacle, PIKE Technologies, USA). The spectra were 
recorded between 4000 and 500 cm-1 with a 2 cm-1 resolution. 
The surface modification (publication II) or residence of different particles in the 
polymeric matrix (publications III and IV) were confirmed by energy dispersive X-ray 
(EDX) spectroscopy or EDX mapping (Oxford INCA 350 EDX, Oxford, UK). 
Quantitative AmQu conjugating efficacy, iron chelating efficiency and the iron leakage 
content (publication I) were measured by spectrophotometric method with UV-1600PC 
spectrophotometer (VWR, U.S.A) or Varioskan Flash fluorometer (Thermo Fisher 
Scientific, USA). 
4.2.2 Quantification of the payloads (I–V) 
For publications I and II, the quantification of the model compounds, the loading degree 
and drug release were evaluated by fluorospectrophotometric method, using a Varioskan 
Flash fluorometer (Thermo Fisher Scientific, USA), while for publication III it was done 
by high performance liquid chromatography (HPLC, Agilent Inc., USA). For publication 
IV, HPLC was used for quantifying ATO and a spectrophotometric method was used for 
DFO. Detailed description of the HPLC experimental setup and conditions used can be 
found in the respective original publications (I–IV). 
The fluorescence quenching (publication I) or FRET (publication II) phenomena caused 
by the interaction between the NPs and the loaded drug were analyzed by 
fluorospectrophotometric methods. 
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4.2.3 In vitro drug release (I–V) 
For publications I and II, the in vitro drug release was performed at 37 °C in sink conditions 
by immersing different NPs in dissolution media with different pH-values (7.4 or 5.0). The 
samples were placed on a shaking plate with a shaking speed of 200 rpm. 100 μL of samples 
were withdrawn from each dissolution test at different time points. The collected samples 
were centrifuged at 16,000g for 5 min and the fluorescence intensity of the supernatants was 
measured. 
To measure the AmQu cleavage from FAP (publication I), AmQu-modified UnTHCPSi 
with a concentration of 50 μg/mL was suspended in a solution with 0.5 mg/mL crude 
protease from bovine pancreas in 2 mL of 6.7 mM PBS (pH 7.4) at 37 °C under constant 
stirring. The solution pH was adjusted by titration with 1.0 M of HCl and/or 1.0 M of NaOH 
to obtain pH-values of 5.0 and 7.4, respectively. Following 8, 12, 20, and 24 h of incubation, 
the NP suspensions were centrifuged to isolate the NPs from the cleaved AmQu, PBS, and 
protease solutions. The AmQu cleaved from the NPs was then quantified with UV-
spectroscopy at a wavelength of 360 nm. 
The in vitro release of XMU-MP-1 from the DPSi/DAu@AcDEX (publication III) was 
evaluated in PBS at pH-values of 7.4 and 5.0 in sink conditions. Due to the low solubility 
of XMU-MP-1, amphiphilic P-188 (5%, w/v) was added to all the release media. The drug-
loaded nanohybrids containing 50 μg of DPSi were added to buffer solutions using a shaking 
plate method at 250 rpm and 37 °C. At each time point, 100 μL of releasing medium was 
centrifuged (4 min, 5,000g) and the supernatant was collected. Then, the same amount of 
preheated medium was added back along with the centrifuged particles to replace the 
withdrawn volume. The concentration of free drugs at each time point was quantified by 
HPLC. Cellular release of XMU-MP-1 from macrophage cells KG-1 was measured by 
dispersing NPs into free IMDM medium or IMDM medium containing 0.5 × 106 KG-1 
macrophage cells. At each time point, 50 μL of the medium was withdrawn and centrifuged 
(4 min, 5,000g) to remove the particles and macrophages. The supernatant was then diluted 
with 50 μL of DMSO to remove the protein binding. The free drug concentration was 
subsequently measured by HPLC. The same amount of preheated medium was added back 
along with the centrifuged particles (or the particles together with macrophage cells) to 
replace the withdrawn volume. After 5 h, the medium containing particles or particles per 
macrophage cells were centrifuged (5 min, 200g) and the supernatants removed. The residue 
was lysated by DMSO (tip sonication for 1 min). After centrifugation (5 min, 16,000g), the 
supernatant was collected and measured by HPLC. The amount of XMU-MP-1 within the 
macrophage cells was calculated as W = Wm+p Wp, where W is the amount of drug within 
the macrophage cells, Wm+p is the amount of the drug in the sample containing both 
macrophage cells and particles, and Wp is the amount of drug in the sample only containing 
the particles. 
The glucose dependent release profiles of nanohybrids/patch composites (publication 
IV) were evaluated with Transwells (Costar 3401, Corning Inc. USA). The particle 
embedded patch (containing 300 μg of PSi) was added to the upper chamber and the donor 
chamber was filled with 3 mL of corresponding PBS buffer, containing 0, 1 or 4 mg/mL of 
glucose. Free drugs embedded in the patch were used as controls. A 100 μL sample was 
collected for ATO quantification, and 200 μL samples were collected for DFO 
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quantification at each time-point, after which 300 μL of pre-heated releasing buffer was 
added in each well. 
4.2.4 Cell lines and culture (I–V) 
Human breast cancer cells (MCF-7, publications I and II), human hepatocellular carcinoma 
cells (HepG2, publications III and V), human bone marrow acute myelogenous leukemia 
macrophages (KG-1, publication III), human umbilical vein endothelial cells (HUVECs, 
publication IV), human dermal fibroblast cells (Fibroblasts, publication IV) and murine 
leukemic monocyte macrophage cells (RAW 264.7 macrophages; publication V) were 
selected for the in vitro studies (all from American Type Culture Collection, USA). The 
MCF-7, HepG2, Fibroblasts and RAW 264.7 macrophages were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, EuroClone S.p.A., Italy) with 4.5 g/L glucose, 
supplemented with 10% fetal bovine serum (Gibco, Invitrogen, USA), 1% nonessential 
amino acids, 1% L-glutamine, penicillin (100 IU/mL), and streptomycin (100 mg/mL) (all 
from HyClone, USA). For the KG-1 cells, Roswell Park Memorial Institute 1640 medium 
was used instead of DMEM for cell culturing. For HUVECs, medium 200 (M200) was used 
with 1× low serum growth supplement (LSGS, Thermal Fisher, USA) for cell culturing. The 
cell cultures were maintained in a standard incubator (BB 16 gas, Heraeus Instruments 
GmbH, Germany) at 37 C with an atmosphere of 5% CO2 and 95% relative humidity. Prior 
to each test, the cells were harvested with trypsin (0.25%, v/v)–ethylenediaminetetraacetic 
acid PBS. 
DOX-resistant MCF-7 cells (MCF-7/DOXR, publication I) were cultured with 
sequential exposure of MCF-7 cells to 1–10 μg/mL of free DOX.255 Each concentration of 
DOX (from low to high concentrations) was added to MCF-7 for one day, and the cells were 
incubated in DMEM medium without DOX for 4 days, followed by repeating the same 
treatment twice and moving to the next higher concentration cycle. 
4.2.5 Cellular viability of the fabricated carriers (I–V) 
The cellular viability of the prepared carriers with and without loaded drugs was evaluated 
using luminescence- based cell viability assays (publications I–V). The assay was 
conducted in 96-well plates (PerkinElmer Inc., USA) and certain amounts of different types 
of cells were seeded in these plates. After the cell attachment and removing of the culture 
media, the wells were washed twice with 1×HBSS (pH 7.4) prior to the addition of the 
fabricated carriers with a series of concentrations, and then incubated for the desired 
exposure times. All assays were conducted at least in triplicate. 
In publication III, to simulate the bio-fate of NPs within the liver, another method was 
carried out. Different concentrations of XMU-MP-1 loaded DPSi/DAu@AcDEX (10, 25, 
50, and 100 μg/mL, DPSi/DAu@AcDEX concentration) and free DPSi, free DAu, free 
XMU-MP-1, free AcDEX, and free DPSi/DAu@AcDEX NPs at corresponding 
concentrations, were incubated with 1×104 KG1 macrophage cells overnight. Then the 
macrophage cells were harvested by centrifuge (900g, 5 min). The macrophages treated 
with different drugs were re-suspended in medium and added to 96-well plates, where 
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HepG2 cells were seeded with a density of 2×104 cells per well. After 24 h of co-incubation 
the viability of different groups was evaluated, as described previously above. 
4.2.6 Embedding TEM images (I) 
For the embedding TEM experiments, the following protocol was followed. After the 
particlecell interaction studies, the PSi suspension was carefully removed and the cells 
were fixed with glutaraldehyde (2%, w/w) in PBS (pH 7.4, 0.1 M) for 30 min at room 
temperature. The wells were then washed twice with sodium cacodylate buffer (NaCac) for 
3 min. Afterwards, the cells were post-fixed with 1% osmium tetroxide in NaCac buffer (pH 
7.4, 0.1 M) and then dehydrated and embedded in epoxy resin. Ultrathin sections (60 nm) 
were cut perpendicular to the insert, post-stained with uranyl acetate and lead citrate, and 
examined with TEM using an acceleration voltage of 120 kV. 
4.2.7 Flow cytometry investigation (I, II, V) 
For publication I, MCF-7 or MCF-7/DOXR Cells (2.0 mL per well) were separately seeded 
in 6-well plates at concentration of 2.5×105 cells/mL. Following 24 h of cell attachment to 
the wells, the cells were first rinsed three times with 1× HBSS (pH 7.4) and then incubated 
with free DOX or DOX@FAP (1 mL, 23 μg/mL, DOX concentration equivalent) for 3 h. 
Then, the samples were removed and the wells washed three times with 1× HBSS (pH 7.4), 
and subsequently cultured for another 4 h. After washing with 1× HBSS (pH 7.4), the cells 
were harvested and fixed with 2.5% glutaraldehyde or 4% of paraffinaldehyde in 1× 6.7 
mM of PBS (pH 7.4) for 30 min at room temperature. For publication II, 100 μg/mL of 
DOX loaded VD-PSi was dispersed in a medium with or without cobalt chloride. The 
following protocol was the same as described above. Exactly 10,000 events were collected 
on a LSR II flow cytometer (BD Biosciences, USA) with a laser excitation wavelength of 
488 nm using FACS Diva software. For publication V, RAW 264.7 macrophage cells were 
separately seeded in 12-well plates at a concentration of 5×105 cells per well. Following cell 
attachment to the wells, the cells were incubated with 10 pg/mL of IFN-γ and 1 μg/mL 
lipopolysaccaride (LPS) for 4 h. Then the cells were washed with 1× PBS (pH 7.4) and 0.5 
mL of 10 μM 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) was added. After 1 h, 
the medium was removed and cells were washed with 1× PBS (pH 7.4) for 3 times followed 
by adding 2, 10, 20 and 50 μg/mL of each PSi sample. After 24 h, the cells were collected 
and measured, as described above. 
4.2.8 In vitro fluorescence confocal imaging (I-II) 
Suspensions of cells (1×105 cells per well) were seeded in Lab-Tek™ Chamber Slides 
(Thermo Fisher Scientific, USA). After 24 h of cell attachment to the wells, Alexa-Fluor® 
633 (Alexa-633) labeled nanocarriers were added into the wells. Following 2 h incubation, 
the samples were removed and the wells were washed three times with 1×HBSS (pH 7.4), 
following culture in DMEM medium with another 0 or 4 h. Afterwards, the medium was 
removed and the wells were washed three times. Cells were fixed with glutaraldehyde (2.5%, 
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w/v) in 1× 6.7 mM of PBS (pH 7.4) for 30 min at room temperature and DAPI (Thermo 
Fisher, USA) with a concentration of 2.8 μM was added for cell staining (publication I). 
Suspensions of cells (1×105 cells per well) were seeded in Lab-Tek Chamber Slides 
(Thermo Fisher Scientific, USA). After 24 h of cell attachment to the wells, the cells were 
cultured with CoCl2 containing medium for 24 h to create hypoxia conditions. Afterwards, 
the cells were rinsed three times with 1×HBSS (pH 7.4), and particles containing 100 μg/mL 
PSi were added into the wells. After 3 and 24 h incubation, the samples were removed and 
the wells were washed three times with 1× HBSS (pH 7.4). CellMask DeepRed (Life 
Technologies, USA) was used to stain the cell membranes by incubating the cells at 37 °C 
for 3 min. Then the cells were washed twice with buffer and fixed with 2.5% glutaraldehyde 
at room temperature for 20 min. The cells were again washed twice with 1× PBS buffer and 
stored in 2 mL buffer (publication II). 
4.2.9 CA IX expression and binding study (II) 
An immunofluorescence study was carried out to confirm the CA IX expression within 
hypoxia conditions. MCF-7 cells were grown on glass coverslips and incubated under 
normoxic and hypoxic conditions. After 48 h, cells were fixed with cold methanol. 
Nonspecific binding was blocked by incubation with PBS containing 2% bovine serum 
albumin (BSA) and 2% FBS. Cells were incubated with CA IX-specific monoclonal 
antibody (mAb) M75 (BioScience, Slovakia) at a concentration of 1:100 for 1 h and then 
incubated with goat antimouse AlexaFluor 488-conjugated IgG antibody (Life 
Technologies, USA) for 1 h. DAPI was used to stain the nuclei. Cell immunofluorescence 
was imaged with Invitrogen EVOS FL Auto Imaging System (Thermo Fisher Scientific, 
USA). ImageJ was used for the quantitative evaluation of fluorescence intensity of FITC 
labeled secondary CA IX antibody in three hypoxic (59 cells in total) and normoxic (53 
cells in total) images. 
Fluorescent thermal shift assay was carried out to determine protein−ligand binding. 
Stopped-flow kinetics CO2 hydration assay was performed using Applied Photophysics 
SX.18MV-R stopped-flow spectrometer. Reaction velocities were measured by recording 
the absorbance of phenol-red indicator (30 μm, λ = 557 nm). A saturated CO2 solution was 
prepared by bubbling the gas in Milli-Q water at 25 °C for 1 h. Serial dilutions with 16 
concentrations of VD11-4-2 compound; PEG-PSi and VD-PSi particles were prepared and 
used for testing the inhibition. Protein CA IX preparation and purification were reported 
previously.253 Samples containing 20 μM CA IX, 0−2 μM ligand (or 0−75 μM particles), 20 
mM of HEPES with 100 mM of NaCl, and 60 μm phenol red at pH 7.5, 10% of FBS, and 
2.5% of EtOH were incubated for 1 h at 25 °C and then used for the stopped-flow 
experiments. Equal volumes of the protein sample and CO2 saturated water were mixed and 
the reaction was observed. Samples without protein (spontaneous CO2 hydration) and 
samples of protein without any inhibitor were used as zero and full activity controls, 
respectively. The Kd values were determined using the Morrison model for tight binding 
inhibitors.256 
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4.2.10 In vitro western blot analysis (III) 
HepG2 cells (2.0 mL per well) were separately seeded in 6-well plates at a concentration of 
5×104 cells/mL. After overnight cell attachment to the wells, free XMU-MP-1 (1, 3, and 10 
μM dissolved in DMSO), and MP@DPSi/DAu@AcDEX (containing the same 
corresponding concentration of XMU-MP-1), DPSi/DAu@AcDEX (containing DPSi at the 
corresponding concentration) were added in the cells. DMSO or H2O2 were added as 
negative and positive controls, respectively. Cells were harvested at 0.5, 3, 6 or 12 h for 
further analysis. 
Cell samples were prepared in ice-cold lysis buffer containing 1% Tritonax-100, 50 mM 
Tris-HCL(pH 7.4), 10% glycerol, 150 mM NaCl, 2 mM EDTA, 50 mM  NaF, 10 mM 
Na3VO4, complete Mini protease inhibitor mixture tablet (Roche), and 2 mM 
phenylmethanesulfonyl fluoride. Total protein contents were determined by a BCA Protein 
Assay Kit (Pierce). Lysate corresponding to 20 µg of total protein was subjected to sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 410% of gradient 
gel, and transferred to polyvinylidene fluoride membranes (100 V, 90 min). 
The proteins were identified by immunoblot analysis with the appropriate primary 
antibodies at a dilution of 1:1000 (or as otherwise stated below). Anti-GAPDH (2118, Cell 
Signaling), anti-MOB1 (13730, Cell Signaling), anti-phospho-MOB1 (Thr35) (8699, Cell 
Signaling), anti-YAP (14074, Cell Signaling), anti-phospho-YAP (S127) (4911, Cell 
Signaling), anti-MST1 (3682, Cell Signaling), anti-MST2 (3952, Cell Signaling). 
Horseradish peroxidase-conjugated antibody to Rabbit IgG (7074) (1:3000 dilution for each) 
were purchased from Jackson ImmunoResearch Laboratories. The protein brands were 
visualized with a SuperSignal West Pico Kit according to the manufacturer’s instructions 
(Thermo Fisher Scientiftic Pierce, USA) 
4.2.12 In vitro PSi degradation study (V) 
To evaluate in vitro PSi degradation kinetics, 150 µg of different PSi were incubated in 3 
mL of 1% Poloxamer 188 PBS buffer (pH 7.4) with or without 3-morpholinosydnonimine 
(SIN-1, 2 mM), under orbital agitation of 100 rpm at 37 °C. At designated time intervals, 
aliquots were sampled and replaced with fresh corresponding degradation buffer. The 
resulting liquid was stored at 4 °C for later analysis of total silicon by Microwave Plasma-
Atomic Emission Spectrometer (Varian Inc. Santa Clara, CA, USA; MP-AES). 
4.2.13 In vitro q-PCR (V) 
RAW 264.7 macrophage cells were seeded in 6-well plates at a concentration of 1.5×105 
cells per well. After incubating overnight, the cells were treated with PSi at concentrations 
of 20 µg/mL. After incubating for 1.5 h, the cells were harvested and total RNA was isolated 
in the presence of Trizol Reagent (Sigma-Aldrich, USA), according to the manufacturer’s 
protocol. The concentration and purity of the RNA preparations were determined by the 
absorbance of RNA at 260 and 280 nm. cDNA was synthesized using the TransScript One-
Step gDNA Removal and cDNA Synthesis SuperMix (Transgen Biotech, China), according 
to the manufacturer’s instructions. Gene expression was detected using a SYBR Select 
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Master Mix (Thermo Fisher, USA) and an ABI Step One Plus Real-Time PCR System. The 
mice primer sequences used in the polymerase chain reaction were shown as follows: TNF-
α: 5' - CAG CCT CTT CTC ATT CCT GCT TGT G - 3', 5' -CTG GAA GAC TCC TCC 
CAG GTA TAT - 3'; CXCL1: 5' - AGC TTC AGG GTC AAG GCA AG - 3', 5' - CTG CAC 
CCA AAC CGA AGT - 3'; CCL2(MCP-1): 5' - AGG TGT CCC AAA GAA GCT GTA - 
3', 5' - ATG TCT GGA CCC ATT CCT TCT - 3'; IL-6: 5' - TAG TCC TTC CTA CCC CAA 
TTT C - 3', 5' -TTG GTC CTT AGC CAC TCC TTC - 3'; IL-1β: 5' - GAA ATG CCA CCT 
TTT GAC AG - 3', 5' - CCA CAG CCA CAA TGA GTG AT- 3'. 
4.3 In vivo evaluation of the fabricated carriers 
4.3.1 Animal model establishment and treatment process (III–V) 
All experiments involving animals were performed in compliance with guidelines under the 
Institutional Animal Care and Use Committee at Experimental Animal Centre in Xiamen 
University, China. Acetaminophen (APAP) induced acute liver failure (ALF) or acute liver 
inflammation (ALI) mice models were correspondingly established in publications III and 
V. Eight- to ten-week-old male C57BL/6 mice were randomly allocated to different groups, 
further administered with APAP (Sigma) via oral gavage after 20 h of starvation. APAP 
was used at a sub-lethal dose of 200 mg/kg for the liver injury study. The treatment initiated 
at 2.5 h post APAP gavage. For publication III, five mice per group received twice a day 
i.v. injections of 15% Solutol® HS 15 (control), DPSi/DAu@AcDEX loading XMU-MP-1 
(0.1 or 0.5 mg/kg), XMU-MP-1 (0.1 or 0.5 mg/kg, dispersed in 15% of Solutol® HS 15) or 
the blank DPSi/DAu@AcDEX control at the corresponding concentration at the indicated 
times post-APAP administration. For publication V, 3 h post ALF model establishment, the 
mice were separately i.v. injected with 0.3 or 3 mg/kg of TO, TC and Un (which were 
referred to as TO L, TO H, TC L, TC H, Un L and Un H), saline was injected as a control. 
The streptozotocin (STZ) induced diabetic model and the following diabetic wound mice 
model were established in publication IV. Male C57BL/6 (20-25 g) mice were treated with 
high fat diet for 4 weeks before the induction of diabetes. Afterwards the mice were 
intraperitoneally (i.p.) injected with STZ (Sigma-Aldrich, US) to induce pancreatic islet β-
cell death. Mice were fastening for 18 h and then weighed prior to injections. STZ was 
freshly dissolved in dilution buffer (0.1 M sodium citrate, pH 4.5, with HCl, stored at 4 °C) 
and filter sterilized. To induce diabetes, the mice were given 0.1 mL i.p. injections of 50 mg 
STZ per kg of body weight for 5 consecutive days. All the mice were fed a high fat diet 
during the process. Blood glucose levels were measured daily beginning 5 days after the 
second i.p. injection. Blood glucose levels were measured for each mouse, and a mouse was 
considered diabetic after two consecutive readings of more than 250 mg/dL blood glucose. 
The diabetic mice were anesthetized with isoflurane and the hair on their backs was shaved 
and completely removed with depilatory cream. After disinfection with alcohol swabs, one 
wound was gently outlined by a marked 6 mm punch biopsy (Acuderm, Fort Lauderdale, 
FL). Following the outline, full-thickness wounds were made using a McPherson-Vannas 
Micro Scissor (World Precision Instruments, Sarasota, FL). The mice were randomly 
divided into 4 groups (n = 5): (1) blank PSi@POD embedded in collagen patch (CP); (2) 
free agents (including ATO, DFO and GOx) embedded in collagen patch (CF); (3) ATO 
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and GOx loaded PSi@POD embedded in collagen patch (PA); and (4) ATO, DFO and GOx 
loaded PSi@POD embedded in collagen patch (PAD). Wounds were further covered with 
Tegaderm and coban. The animals were individually caged, and the various treatments were 
reapplied every 3 days. Wounds were photographed with a digital camera, and the wound 
area was calculated with Image J.  
4.3.2 Histological analysis (III–V) 
For publication III, the mice were sacrificed at 12, 24 and 72 h post treatment, and the 
dissected liver tissues were fixed in buffered formalin, embedded in paraffin, and then 
processed for tissue-section staining with hematoxylineosin (H&E). Transferase-mediated 
deoxyuridine triphosphate-biotin nick end labelling (TUNEL), C-X-C chemokine receptor 
type 4 (CXCR-4) assays were performed according to the manufacturer's instructions, using 
the Apoptag Peroxidase in Situ Apoptosis Detection Kit (Millipore). The rest of the tissues 
were snap frozen in liquid nitrogen and subsequently stored at 80°C. 
For publication IV, wounds were harvested on days 7 and 14 with a 3 mm rim of 
unwounded skin for histological analysis. The samples were fixed in 4% paraformaldehyde 
overnight, embedded in paraffin and then sectioned (5 μm slabs(?)). The length of the new 
epidermis was used to evaluate the wound healing conditions after H&E staining. Ki-67 
staining was used to investigate the regeneration process at days 7 and 14. ZEISS Axioskop 
microscope was used for capturing digital photographs and Image J software was used to 
evaluate the wound healing process. 
For publication V, the mice were sacrificed at 48 h post PSi administration and the liver 
tissues were processed as described above, followed by conducting the H&E staining. 
4.3.3 In vivo immunofluorescence imaging (III–V) 
For publication III, solutions of Alexa-488 labled DPSi/DAu@AcDEX (within which DPSi 
was labeled) was prepared at concentrations 0.1 mg/mL (DPSi concentration), and a NP 
solution containing 1 mg/kg of DPSi was injected into healthy or ALF C57BL/6 mice via 
the tail vein. After 24 h, the mice were narcotized via chloral hydrate and the liver was 
perfused by paraformaldehyde. The liver was then collected and prepared for histologic 
section. Before confocal imaging, all the slices were stained by DAPI to image the nucleus, 
and F4/80 ab90247 was used to stain the macrophages. The confocal images were taken 
with a Zeiss LSM 780 (Carl Zeiss, Germany) inverted confocal microscope, equipped with 
argon (488 nm), UV (diode 405 nm) and HeNE (594 nm) lasers. 
For publication IV, the harvested skin tissues were embedded in an optimal cutting 
temperature compound (OCT) and frozen in liquid nitrogen for fluorescent immunostaining. 
7 µm thick frozen sections were blocked in 10% normal goat serum/0.05% Triton X-100/0.2% 
BSA (Sigma) in PBS for 40 min at room temperature. The sections were incubated overnight 
at 4 °C with a CD31 (PECAM-1) antibody (1:200, sc-1506r, Santa Cruz, USA), followed 
by incubation with goat anti-mouse IgG-TR (Texas Red) secondary antibody for 1 h at 37 °C. 
DAPI (Sigma) was used to stain the nuclei for 10 min. Subsequently, sections were imaged 
with fluorescence microscopy. Microvessel density (MVD) was assessed in the wound bed 
under 200× magnification for each specimen. Subsequently, the microvessel numbers were 
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counted at 200× magnification within the hot spot area. Only the vessels with clear clusters 
of endothelial cells with lumen were counted. The MVD value was defined as the average 
vessel count in 5 specimens. 
For publication V, all liver slices were conducted with TUNEL staining with the nuclei 
stained with DAPI as described above. 
4.3.4 In vivo and ex vivo western blot analysis (III–V) 
For publication III, fresh liver tissue samples from wild-type mice or ALF mice with 
different formulations were collected or stored under -80 °C, and then prepared and 
analyzed as described above. 
For publication IV, fresh skin tissue samples were prepared in ice-cold lysis buffer, as 
described above. Lysate corresponding to 20 µg of total protein was subjected to SDS-
PAGE, and transferred to polyvinylidene fluoride membranes (100 V, 90 min). 
The proteins were identified by immunoblot analysis with the appropriate primary 
antibodies at a dilution of 1:1000 (or as otherwise stated below). Anti-β-actin (A1978, 
Sigma-Aldrich), anti-Hif-1α (10006421, Cayman Chemical), anti-VEGF (19003, 
Proteintech). Biotinylated secondary antibody to Rabbit IgG (BAF008 1:5000 dilution for 
each) was purchased from R&D System. The protein brands were visualized as described 
above. 
For publication V, 3 h post ALI-establishment mice were sacrificed and the plasma (ALI 
plasma) was collected from heart blood, while blank plasma was collected from healthy 
mice (healthy plasma). DMEM medium containing 10% of healthy plasma and ALI plasma 
were referred to as healthy medium and ALI medium, correspondingly. Healthy and ALI 
media with or without PSi at a concentration of 20 μg mL-1 were incubated with RAW 
macrophage cells for 1 h. Then the cell samples were prepared as described above. The 
proteins were identified by immunoblot analysis with appropriate primary antibodies at a 
dilution of 1:1000 (or as otherwise stated below). The antibodies used are as follows: Anti-
NF-κB (SC-372, Santa Cruz), anti-p-IκBα (2859s, CST), anti-IκBα (SC-371, Santa Cruz) 
Anti-β-Actin (A5316, Sigma). Biotinylated secondary antibody to mouse IgG (A28177) or 
Rabbit IgG (BAF008 1:5000 dilution for each) were separately obtained from Invitrogen or 
R&D System. The protein brands were visualized as described above. 
4.3.5 Whole blood and serological analysis (III, V) 
Whole blood cell analyses were conducted by an automatic biomedical analyzer (VetScan 
HM5, ABAXIS, USA) according to the manufacturer’s instruction. To assess the injurious 
effects of APAP on liver histology and function, serum was collected from mice via orbit 
puncture. Serum samples were taken at indicated post-APAP time points of 12, 24 and 72 h 
(publication III) or 48 h post PSi injection (publication V). Alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) levels were determined in blood specimens using 
ALT/AST assay kit (C010-1; NJJCBio, China, publication III) and measured by Varioskan 
plate reader (Thermal Fisher, USA) or using ALT/AST assay kit (140118005, 140218004, 
Mindray, China, publication V) and measured by an automatic biomedical analyzer 
(VetScan HM5, ABAXIS, USA). 
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4.3.6 In vivo computed tomography (CT) imaging (III) 
Prior to conducting in vivo CT imaging, the particle concentration dependent hounsfield 
unit (HU) increase was first measured. Deionized water was used as a control. All the 
samples were scanned on a positron emission computed tomography (PET)/CT system 
(Mlabs U-CT, Netherlands) and the images were obtained at an X-ray voltage of 80 kVp, 
anode current of 500 μA in accurate mode, and full angle with 3 frame averaging. The CT 
contrasting effect of DPSi/DAu@AcDEX, was evaluated with C57BL/6 mice (body 
weights: 1822 g). All the mice were scanned on the same machine. The images were 
obtained at an X-ray voltage of 55 kVp, and anode current of 615 μA in accurate mode using 
full angle and 3 frames averaging. Healthy or ALF mice were anesthetized by isoflurane 
inhalation. The injection volume of contrast agent for each mouse was 200 μL with a dose 
of 20 mg DAu equiv./kg. The CT imaging was taken at 0, 4, 30, or 90 min post injection. 
4.3.7 Assessment of cellular cytokines release by ELISA methods (IV, V) 
For ELISA analysis in publication IV, fresh wound samples were harvested and stored at 
80 °C, and all skin samples were prepared in ice-cold saline. IL-1β, IL-6 and TNF-α levels 
were analyzed in the same supernatants by using the BD OptEIA human ELISA Set II (cat. 
557953, 555244, BD Bioseciences, USA). All assays were performed according to the 
manufacturers’ instructions. Absorbance was measured at 450 nm with a SpectraMax M5 
microplate spectrophotometer, and cytokine quantities were calculated through standard 
curves for each recombinant cytokine. 
For publication V, both in vivo and ex vivo ELISA tests were performed. For in vivo 
ELISA tests, liver samples from each mice were harvested and stored at -80 °C, and all liver 
samples were prepared in ice-cold saline. Then cytokine levels were measured as described 
above. 
For ex vivo ELISA tests, healthy and ALI medium with or without PSi at a concentration 
of 20 μg mL-1 were incubated with RAW macrophage cells for 24 h, and IL-1β, IL-6 and 
TNF-α levels in blank healthy medium, blank ALI medium and the corresponding cell 
culturing medium were analyzed, as described above. 
4.3.8 Ex vivo and in vivo real-time quantitative polymerase chain reaction 
(qPCR) analysis (V) 
For ex vivo qPCR experiments, RAW 264.7 macrophage cells were seeded in 6-well plates 
at a concentration of 1.5×105 cells per well. After incubation overnight, the cells were 
treated with healthy medium and ALI medium with or without 20 μg mL-1 of each type of 
PSi. After incubating for 1.5 h, total RNA was isolated and analyzed, as described above. 
For in vivo qPCR experiments, liver samples from each mice were prepared and 
analyzed as described above.   
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4.3.9 Brief protein corona analysis (V) 
80 μg of each type of PSi was incubated in 4 mL of 40% healthy or ALI plasma in DMEM 
medium at 4 °C for 4 h. After incubation, the NPs were collected by centrifugation and 
washed twice with Milli-Q water. The proteins were extracted from the plasma treated NPs 
with SDS-PAGE. The opsonized NPs (40 μg) were suspended in the PAGE sample buffer 
(125 mM of Tris-HCl, pH 6.8, 2% of SDS, 5% of glycerol, 0.002% of bromophenol blue) 
and incubated at 100 °C for 5 min in order to release and denaturate the adsorbed proteins. 
The samples were run on a 9% SDS-PAGE-gel for 2 h at a constant voltage of 100 V. The 
gel was stained with 0.025% Coomassie brilliant blue (Thermo Scientific, USA).  
4.3.10 Proteomics of different PSi protein corona (V) 
Mass Spectrometry (MS)-based shotgun proteomics was employed to study the varying 
composition of protein coronas from different PSi. ALI plasma was collected as described 
above, and further incubated with TO, TC and Un at a concentration of 20 μg/mL for 4 h. 
Afterwards, proteins were digested with trypsin and peptides were labeled with isobaric tags 
for relative and absolute quantification (iTRAQ), and quantified by LC-MS/MS (see Ref.257 
for detailed information about mass spectrometry-based peptide quantification using 
iTRAQ). 
4.3.11 Statistical analysis 
Results are expressed as mean ± standard deviation (SD) or mean ± standard error of mean 
(SEM). The statistical difference were analyzed using two-tailed paired-samples Student’s 
t test (and nonparametric test) via Graphpad Prism (Graphpad softward, USA). The level of 
significance was set at probabilities of *p < 0.05, **p < 0.005, and ***p < 0.001 when 
comparing viability and flow cytometry results in publication I, and *p < 0.05, **p < 0.01, 
***p < 0.0005 and ****p < 0.0001 for publications II-V 
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5 Results and discussion 
Depending on the physicochemical properties of the payloads, different strategies should be 
applied to fulfill the preferred release profile(s). Herein, a series of PSi-based 
nanocomposites/nanohybrids were constructed to load/co-load hydrophilic and 
hydrophobic drugs. Further multi-functionalities were simultaneously achieved, according 
to the specific requirements for different biomedical applications. 
5.1 Hydrophilic drug (DOX) loaded multifunctional PSi 
nanocomposites for cancer therapy (I) 
PSi has been widely investigated for advanced DDS due to its attractive properties. However, 
due to the freely accessible pores, bare PSi has several deficiencies in controlling the release 
of drugs, especially of hydrophilic drugs. In the first two studies of this thesis, the aim was 
to fabricate PSi-based nanocomposites for the hydrophilic anti-cancer drug DOX, for 
loading and pH-responsive release, and for further applications of potential anti-cancer 
efficacy. To achieve this, in publication I, a ligand to feasibly modify PSi was designed and 
synthesized. This nanosystem inherits several advanced properties in a single carrier, 
including promoted anticancer efficiency, multiple drug resistance (MDR) reversal, stimuli-
responsive drug release, drug release monitoring, and enhanced particlecell interactions. 
5.1.1 pH-sensitive drug release behavior of the nanosystem 
A pH-sensitive metal-drug complex was applied in the design of the system for hydrophilic 
drug loading. Inspired by the structure of dopamine, 3-aminopropoxy-linked quercetin 
(AmQu), a derivative of a natural anti-cancer flavonoid was designed and subsequently used 
to modify PSi (Figure 9A). The successful synthesis of AmQu was confirmed by 1H NMR 
and 13C NMR. Successful conjugation of AmQu was confirmed by FTIR and UV-vis spectra 
(see Figure S3 in publication I). Moreover, the following iron ion chelation was confirmed 
by energy dispersive X-ray spectroscopy (EDX, see Figure 2 in publication I). The DOX 
loading capacity of Fe3+-AmQu-UnTHCPSi (FAP) was 24 ± 2% (w/w), higher than the 
loading capacity of bare UnTHCPSi (10 ± 1%, w/w). In addition, after DOX was loaded 
into the particles, its fluorescence was quenched (Figure 9B), probably due to the 
interaction between DOX and the anthocyanidin ring structure within the AmQu through an 
electron transfer mechanism.258 This feature may further be applied to monitor the drug 
release behavior. 
In vitro DOX release behavior was also investigated. In the bare UnTHCPSi most of the 
loaded DOX was burst-released within 1 h of incubation in the release medium. For DOX-
loaded in FAP (DOX@FAP), when the pH-value was 7.4, only about 14.8 ± 0.9% of DOX 
was released within 4 h, and no clear extra DOX was released in the following 20 h. 
However, the released drug amount was significantly increased when the pH-value was 
more acidic, as 77.3 ± 1.6% of DOX was released at pH 5 within 24 h (Figure 9C). 
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Figure 9. (A) Synthesis process for FAP/DOX PSi-modified nanocomposites. Abbr. EDC, 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide; NHS, N-hydroxysuccinimide; Et, ethyl. 
(B) Fluorescence spectra of DOX before and after release from FAP, λex = 490 nm. In 
vitro DOX release curves of UnTHCPSi and FAP at pH 5 and pH 7.4 PBS buffer at 
37 °C within 24 h. Data are shown as mean ± SD (n = 3). Figures were reprinted with 
permission from publication I. 
5.1.2 Potential application in DOX-resistent cancer treatment and imaging 
One of the most challenging obstacles in NP surface modification is to achieve the concept 
that one ligand can accomplish multiple purposes. The modification of AmQu could not 
only endow PSi with pH-responsive DOX release behavior, due to the similar structure 
between AmQu and dopamine, but it could also enhance the particlecellular interaction of 
FAP compared to bare PSi, which was observed from the fluorescence intensity assisted 
quantitative analysis and the corresponding confocal imaging (Figure 10A(a)). In addition, 
the stimuli-induced drug release was correlated with the recovery of fluorescence, thus 
giving real-time information about the stimuli-dependent drug release, as only the 
fluorescence of DOX could be observed when the drug was intracellularly released while 
no obvious fluorescence signal was observed when the drug was still residing in the vehicle 
(Figure 10A(b)). Moreover, the anti-cancer efficiency of the developed nanocomposite was 
tested on a DOX-resistant human breast cancer cell line, DOX/MCF-7R, and a statistically 
significant difference was observed between DOX@FAP and free DOX (37 ± 1% vs. 65 ± 
2%, ***p< 0.001) (Figure 10B). This could not only be explained by the promoted cellular 
uptake of FAP as described above, but also due to the anti-cancer effect of AmQu, which 
can be cleaved from FAP when endocytosized by cancer cells (Figure 10C). Indeed, the 
anticancer efficiency of free AmQu + free DOX was higher than that of DOX alone (44 ± 
3% v.s. 65 ± 2%, **p< 0.005). Previous results have confirmed the anti-cancer and drug 
resistance reversing ability of quercetin, and 4'-OH and 7-OH groups within the quercetin 
structure are necessary for this activity.259 Herein, we specifically modified the 3-OH moiety 
of quercetin, and therefore a better anticancer effect was expected. 
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Figure 10. (A) (a) Quantitative cellular uptake of different particles by DOX/MCF-7R. Error bars 
represent standard deviation (n = 3), *p < 0.05 and ***p < 0.005. (b) Confocal 
microscope images of Alexa-Fluor 488 conjugated particles interacting with 
DOX/MCF-7R cells after incubation at 37 °C for 3 h. All scale bars are 20 μm. (B) 
Confocal images of Alexa-Fluor 633 conjugated NPs (red) interacting with 
DOX/MCF-7R cells after incubation at 37 °C for 2 h, followedg by immediate imaging 
or after incubating for another 4 h. All scale bars are 8 μm. (C) Cell viability of 
DOX/MCF-7R breast cancer cells treated with different formulations. The 
concentration indicates the amount of UnTHCPSi; for other agents the concentration 
is equivalent to the corresponding concentration within FAP. Data are shown as mean 
± SD (n ≥ 3). Figures were reprinted with permission from publication I. 
5.2 Hydrophilic drug loaded PSi nanocomposites for cancer 
targeting (II) 
In addition to pH-responsive hydrophilic drug release and multi-functionalities for anti-
cancer therapy applications, it would be preferred to simultaneously obtain a specific 
targeting ability. In publication II, a versatile carbonic anhydrase IX (CA IX, a specific 
protein expressed in the outer cell membrane of cancer cells in hypoxia conditions) targeting 
nanocomposite was constructed. The fluorescence properties of the ligand also equipped the 
nanocomposites with imaging capabilities. 
5.2.1 Characterization and DOX loading/release studies of the 
nanocomposites 
A novel CA IX targeting ligand VD11-4-2 was applied to modify PSi. VD11-4-2 was 
conjugated on PSi particles (VD-PSi), as illustrated in Figure 11A. The DOX loading 
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degree of VD-PSi was higher than that of bare PSi (21.4 ± 0.1% vs. 10.1 ± 0.1%, w/w). This 
may be caused by the hydrogen bond formation between VD11-4-2 and DOX. UV-Vis 
spectrum of DOX-loaded VD-PSi (DOX@VD-PSi) confirmed the initial hypothesis. 
Compared to free DOX and VD11-4-2, the spectrum of DOX@VD-PSi showed a clear red 
shift for DOX and VD11-4-2, which was the main characteristic for hydrogen bond 
formation (Figure 11B). A pH-responsive DOX release was also observed from 
DOX@VD-PSi, mainly due to NH3
+ formation in the acidic solution, which reduced the 
number of hydrogen-bond-forming acceptors and therefore weakened the overall hydrogen-
bonding interactions (Figure 11C). 
 
Figure 11. (A) Scheme of the VD-PSi fabrication. (B) UV−Vis absorption spectra of DOX, VD11-
4-2, and DOX@VD-PSi in aqueous solution indicating the hydrogen bond between 
VD11-4-2 and DOX. (C) In vitro DOX release curves of DOX@PSi and DOX@VD-
PSi at different pH-values. Data is shown as mean ± s.d. (n = 3). Figures were reprinted 
with permission from publication II. 
5.2.2 Enhanced cancer targeting and potential application in imaging 
Immunofluorescence analysis was carried out to verify the exclusive expression of CA IX 
in MCF-7 cells under hypoxic conditions. Afterwards, the capability of VD-PSi to inhibit 
CA IX catalytic activity was evaluated and compared to the free compound VD11-4-2: VD-
PSi showed a similar inhibition effect towards CA IX catalytic activity, but presented a 
higher equilibrium dissociation constant (KD) value (Figure 12A). This minor difference 
was partly due to the immobilized compound being inaccessible to the protein. The anti-
cancer effect of DOX@VD-PSi was evaluated under normoxia and hypoxia conditions. 
Under normoxia, DOX@VD-PSi showed less of an anti-cancer effect compared to free 
DOX, due to the detained DOX release and decrease in cellularparticle interactions as a 
result of the PEG modification. However, under hypoxia, which can better mimic the solid 
tumor environment, a prominent DOX resistance was observed, and the DOX@VD-PSi 
formulation showed the highest killing ratio among all the study groups. Moreover, extra 
addition of free VD11-4-2 could dampen the effect, partly proving the hypoxia induced 
cancer targeting effect by VD-PSi (Figure 12B).  
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VD11-4-2 obtained special fluorescence properties with a λex of 360 nm and λem of 500 
nm. This distinctive fluorescence feature may assemble a system resulting in the formation 
of a FRET complex: a donor VD11-4-2 energy transfer to the acceptor DOX (λex = 490 nm, 
λem = 600 nm), where the fluorescence of VD11-4-2 was quenched as a result of DOX 
absorbance. The fluorescence spectra of VD-PSi before and after DOX loading (λex = 360 
nm) confirmed the initial hypothesis (Figure 12C), further suggesting the potential of 
applying VD-PSi to monitor the DOX release behavior via fluorescence imaging. Confocal 
laser scanning microscopy experiments were conducted to confirm the hypothesis about 
using the FRET effect between VD11-4-2 and DOX to monitor the drug release. While 
DOX is inside the particles (3 h incubation), 360 nm wavelength excites VD11-4-2 and the 
energy from VD11-4-2 transfers to DOX; thus, a DOX fluorescence signal (∼600 nm) was 
observed with no notable VD11-4-2 fluorescence (∼500 nm). After DOX was released from 
the particles, and the distance between DOX and VD11-4-2 was larger than the typical 
limiting distance of FRET (about 10 nm), the VD11-4-2fluorescence signal was observed 
(Figure 12D). 
 
Figure 12. (A) CA IX protein inhibition determined by stopped-flow kinetics CO2 hydration assay. 
The lines were fitted according to the Morrison model. (B) Normoxia (a) and hypoxia 
(b) cellular viability results of MCF-7 cancer cells treated with different concentrations 
of DOX in different formulations for 48 h. The concentration indicates the amount of 
PSi; for the other compounds the concentration was equivalent to the corresponding 
concentration within VD-PSi. Data are shown as mean ± SD (n ≥ 3). (C) Fluorescence 
intensity of VD-PSi and DOX@VD-PSi at PSi concentration of 5 mg/mL with λex = 360 
nm. (D) Confocal microscope images of DOX@VD-PSi interacting with MCF-7 cells 
after incubation for 3 and 24 h under hypoxic conditions. Figures were reprinted with 
permission from publication II. 
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5.3 Hydrophobic drug loaded PSi nanohybrids for theranostic liver 
regeneration (III) 
Hydrophobic PSi has been shown to improve the solubility and bioavailability of 
hydrophobic drugs, making it a good candidate for hydrophobic drug loading. To better 
control the drug release profile, microfluidic-assisted nanoprecipitation was carried out to 
encapsulate different particles within one polymer matrix by simply altering their surface 
properties. The nanohybrids also can act as contrasting agents for CT imaging due to the 
presence of Au NPs in the polymer matrix. Due to the major accumulation of the 
nanohybrids in the liver, the constructed nanohybrids were loaded with a hydrophobic small 
molecule (XMU-MP-1) with effective regenerative capability,260 intended for further 
applications in acute liver failure (ALF) theranostics. 
5.3.1 Characterization 
Un PSi was adopted in the study due to its feasible surface modification properties. pH-
responsive polymer AcDEX was used to encapsulate both PSi and Au NPs. A schematic 
illustration of the procedure to prepare the DPSi/DAu@AcDEX by microfluidics is shown 
in Figure 13A, demonstrating a single-step, simultaneous co-encapsulation of different NPs. 
After encapsulation, PSi with irregular shape (Figure 13B(a)) and small-sized gold 
nanoparticles (~ 5 nm, Figure 13B(b)) were fully covered by AcDEX matrix and new 
nanohybrids were formed containing both types of particles with spherical morphology 
(Figure 13B(c-d)). 
 
 
Figure 13. (A) Schematic illustration of the procedure to prepare the DPSi/DAu@AcDEX by 
microfluidics. (B) TEM images showing morphologies of (a) PSi, (b) Au, (c, d) 
DPSi/DAu@AcDEX at each step and the corresponding EDX spectrum. Figures were 
reprinted with permission from publication III. 
5.3.2 Drug loading/release behavior 
Without PSi, the drug loading degree within the polymer matrix was as low as 0.04% with 
the same loading procedure, whereas a loading degree of 7.8% was achieved by applying 
PSi. The outer layer of the pH-sensitive polymer AcDEX will render the nanohybrids to 
release the drug only in an acidic environment, which occurs within the intracellular 
environment. The in vitro release study showed that only 13.1 ± 2% of the loaded drug was 
released within 5 h at extracellular pH (7.4), while the amount released  increased to over 
48 
 
90% at intracellular pH (5.0) (Figure 14A). Indeed, when co-incubating the particles and 
macrophages (KG1) cells, a drug release augmentation was observed compared to blank 
medium (Figure 14B). This was mainly due to the cellular internalization induced drug 
release in the endosomes. Subsequently, XMU-MP-1 with high permeability could 
penetrate through the membrane of KG1 and potentially reach the extracellular medium, 
suggesting that the nanohybrid interacted with the target cells (hepatocytes) in an indirect 
manner. Western blot results further confirmed this cellular uptake dependent drug release 
profile. HepG2 was co-incubated with drug loaded nanohybrids 
(MP@DPSi/DAu@AcDEX) over time. The inhibition of key proteins’ expression, 
phosphorylated Mps one binder (p-MOB) and phosphorylated Yes-associated protein (p-
YAP), became prominent from 3 h to 12 h, which was mainly induced by time-dependent 
particle uptake triggered drug release, suggesting that the nanohybrids could serve their 
function in a direct manner (Figure 14C). 
 
Figure 14. (A) In vitro XMU-MP-1 release curves at pH 5 and 7.4 in PBS containing 5% of P-188 
at 37 ºC within 5 h. (B) XMU-MP-1 release curve in RPMI medium, containing KG1 
macrophages at 37 ºC  within 5 h. Data are shown as mean ± SD (n ≥ 3), **p < 0.01. 
(C) Relative phosphorylation levels of MOB and YAP (p-MOB and p-YAP) in HepG2 
with different formulation treatments over time (3 to 12 h). The corresponding panels 
(from left to right) are: control, dimethyl sulfoxide (DMSO)–treated control, H2O2-
treated control, DPSi/DAu@AcDEX with low, medium and high concentration (from 
left to right), free XMU-MP-1 (1, 3, and 10 μM from left to right, dissolved in DMSO), 
and MP@DPSi/DAu@AcDEX (containing the same amount of XMU-MP-1 at the 
corresponding concentration). Figures were reprinted with permission from 
publication III. 
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5.3.3 In vivo ALF theranostic evaluation 
ALF model was established by the overdosed administration of acetaminophen (APAP), 
which is also a common cause of ALF worldwide. Serum alanine aminotransferase (ALT) 
and aspartate transaminase (AST) levels at different time points quantitatively confirmed 
the overall better alleviation of hepatic damage by MP@DPSi/DAu@AcDEX compared to 
free drug (see Figure 3C in publication III). This was further qualitatively confirmed by 
TdT-mediated dUTP Nick-End labeling (TUNEL) staining (Figure 15A). Moreover, 
MP@DPSi/DAu@AcDEX obtained better cardiac compliance at high drug concentration 
(3 mg/kg for XMU-MP-1), as the hydrophobic free drug precipitated out and caused 
myocardial infarction at high dose, while this phenomenon was averted by applying the 
nanohybrids (Figure 15B). 
 
 
Figure 15. (A) TUNEL staining of liver sections at different time-points. ALF model was 
established by 200 mg/kg APAP gavage administration. The treatment was initiated 
2.5 h post APAP gavage. ALF mice were administrated with different formulations 
twice daily. (B) CXCR-4 immunohistochemical staining heart sections at 72 h after 
administrating free drug or MP@DPSi/DAu@AcDEX (with 3 mg/kg of XMU-MP-1), 
suggesting enhanced compliance with the application of nanohybrids. (C) 
Immunofluorescence images of ALF liver after i.v. administration with Alexa-488 
labeled DPSi/DAu@AcDEX. (D) In vivo CT images of healthy or ALF mice with or 
without i.v. administration of DPSi/DAu@AcDEX. Detailed concentrations and sample 
preparation methods can be found in the corresponding paper. Figures were reprinted 
with permission from publication III. 
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The potential rationale for the enhanced treatment index of MP@DPSi/DAu@AcDEX 
was due to the lesion site specific accumulation of the particles. Immunofluorescence 
imaging demonstrated that the immune cells were recruited and accumulated at lesion sites 
after ALF establishment and the NPs were co-localized within the macrophages, thus 
resulting in targeted accumulation within the damaged part (Figure 15C). Taking advantage 
of this property, the co-resided Au NPs were applied as contrasting agents for CT imaging 
for lesion detection and characterization. For ALF mice, after i.v. injection of 
DPSi/DAu@AcDEX, a distinguishable area was generated 30 min post-injection, while no 
clear signal was observed from healthy mice, which is promising for early stage ALF 
diagnosis (Figure 15D). Altogether, these results support the idea of developing 
nanohybrids as potential theranostic platforms for ALF. 
5.4 Dual-drug loaded PSi nanohybrids for tissue regeneration (IV) 
Simultaneous incorporation of two drugs with different physiochemical properties into a 
single carrier was achieved. A deliberately designed oxidation responsive polymer was 
synthesized to encapsulate a hydrophobic drug loaded PSi that dynamically conjugated a 
hydrophilic drug. Furthermore, the orchestrated cascade from wound detection, ROS 
scavenge, and drug release to hydrogel formation was initiated by the specific disease status, 
therefore bio-mimetically enhancing the tissue regeneration effect.  
5.4.1 Characterization and close-loop degradation of the nanohybrids 
An oxidation responsive polymer, POD, was synthesized by modifying ODEX with 
phenylboronic pinacol ester, which was further applied into encapsulating hydrophobic drug 
(ATO) loaded PSi to form ATO loaded PSi@POD. Due to the excess aldehyde groups from 
ODEX, the newly formed nanohybrids were simultaneously anchored with the amine group 
containing GOx and deferoxamine (DFO) through a pH-sensitive dynamic bond Schiff-base 
formation (D-G-PSi@POD). To facilitate further in vivo applications, the nanohybrids were 
integrated onto collagen patches. The introduction of GOx endowed the system with the 
ability to respond to surrounding glucose levels as it can catalyze glucose oxidation, and 
generate gluconic acid and H2O2. Gluconic acid decreased the surrounding pH-value and 
triggered the DFO release, and the pernicious side product H2O2 could be close-loop 
consumed by POD, synchronously releasing the loaded ATO. Furthermore, the degradation 
product of POD, ODEX, formed in situ into a hydrogel embedded within a collagen patch. 
This in situ NP/hydrogel transformation created a moist environment around the wound bed, 
altering the stiffness of the patch to better mimic the elastic properties of the natural soft 
tissues (Figure 16A). The produced PSi-encapsulated nanohybrids are shown in Figure 
16B, and after embedding on the collagen patch, a nano-network was formed (Figure 16C). 
TEM images confirmed the glucose triggered close-loop particle degradation. An integrated 
PSi@POD structure was still observed after 24 h incubation without addition of glucose. 
However, the shell structure of POD was barely observed at 4 mg mL-1 of glucose, and at 1 
mg mL-1 of glucose only an indistinct polymeric layer was found (Figure 16D). The 
degradation product ODEX can further function as a cross-linker to form into a hydrogel 
with the collagen-ark in situ, and thereby the inherent flaw of collagen patches, namely low 
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stability and poor mechanical properties, would be partially solved. Oscillatory stress sweep 
tests were carried out to confirm the enhanced viscoelastic property. Figure 16E shows that 
a structure breakdown occurred at higher shear stress when adding ODEX or PSi@POD, 
where the collagen + PSi@POD + 4 mg mL-1 glucose (CP4) obtained the highest stiffness 
enhancement. Despite the same cross-linker (ODEX) concentration, the reason for the 
higher viscoelastic property of CP4 could be explained by the local pH value decrease as a 
result of gluconic acid production. This could allow the fibers of collagen to repel against 
each other and to de-aggregate, further facilitating the interactions between collagen and 
ODEX.261 
 
Figure 16. (A) Scheme of the dynamic close-loop nanohybrids construction and the following 
biomedical applications for diabetic wound healing. (B) TEM image showing the 
morphologies of D-G-PSi@POD. (C) SEM image showing the nanohybrids embedded 
collagen patch. (D) TEM images of D-G-PSi@POD with different concentrations of 
glucose at 24 h, suggesting a glucose dependent dissassembly behavior of the 
nanosystem. (E) Rheological dynamic oscillatory stress sweep tests of different 
hydrogels. The solid data points correspond to the storage moduli G′. The open data 
points correspond to the loss moduli G″. black square, black circle, green down-
triangle, blue right-triangle and red diamond respectively correspond to collagen (C), 
collagen+ODEX (COD), collagen+PSi@POD (containing the same concentration of 
ODEX, CP), collagen+PSi@POD+1 mg/mL glucose (CP1) and 
collagen+PSi@POD+4 mg/mL glucose (CP4). Figures were reprinted with permission 
from publication IV. 
5.4.2 In vitro dual drugs release  
We further investigated the dual-drug release profiles of D-G-PSi@POD in vitro (Figure 
17). Transwell-assisted method was applied here, where the D-G-PSi@POD embedded 
collagen patch was loaded in the upper chamber, and drugs’ concentrations were monitored 
in the donor chamber. For free drugs loaded collagen patches, over 97% of the drugs were 
released during the first 3 h, whereas only 9.5 ± 1.4 % of ATO and 35 ± 2.9 % of DFO were 
released after 72 h without glucose addition, when the nanohybrid was employed. 
Cumulative ATO/DFO release was significantly higher when the glucose concentration was 
increased. After 72 h the cumulative release of ATO/DFO was 57 ± 2.7% and 71 ± 22%at 
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the glucose concentration of 1 mg mL-1, and the release values increased to more than 90% 
at a glucose concentration of 4 mg mL-1. This glucose dependent release profile may further 
lead to stage-specific drug release from the patch when applied in vivo. As the local glucose 
content in a diabetic wound bed is highly correlated to the diabetic condition and tissue 
repairing process, and thus the drug release rate is biomimetically related to the healing 
process. With the closure of the dermis gap, fewer blood and tissue exudates can infiltrate 
into the wound bed, thus altering the release behavior of both drugs, and benefitting the 
therapeutic efficiency and rehabilitation. 
 
Figure 17. Release profiles of ATO (A) and DFO (B) from a D-G-PSi@POD embedded collagen 
patch. The release was conducted in 1× PBS buffer (pH = 7.4) with 0, 1 or 4 mg mL-1 
glucose. Free ATO and DFO were directly added in collagen patches and were used 
as the control. Data represent mean ± SD (n = 3). Figures were reprinted with 
permission from publication IV. 
5.4.3 Biomimetically stage-specific enhanced regeneration  
Streptozotocin (STZ)-induced diabetic mice with full thickness wounds were used to 
evaluate the in vivo performance of the system for diabetic wound closure. The mice were 
randomly divided into four groups (n = 5) and topically administrated with different samples, 
including (1) collagen patch with blank PSi@POD (CP), (2) collagen patch with free ATO, 
DFO and GOx (CF), (3) collagen patch with ATO/GOx loaded PSi@POD (PA), and (4) 
collagen patch with ATO/DFO/GOx loaded PSi@POD (PAD). The PAD group showed the 
best healing efficiency in the early stage. However, the healing rate of the PAD group was 
detained after day 6, while the wound closure rate of CF group was not interfered (Figure 
18A). This was caused by the fact that less tissue exudate and bleeding limited the release 
of drugs from the nanosystem. Yet the release of free drugs was not affected. This 
biomimetically altered regeneration capability is beneficial for tissue engineering, as long 
term uncontrolled regeneration may bring detrimental side effects.262 To better explore this 
phenomenon, immunofluorescence staining for CD31 was studied to investigate the 
distribution of micro-vessels in the regenerative dermis near the wound bed, and the 
microvessel density (MVD) was semi-quantitatively evaluated (Figure 18B). At day 7, the 
MVD of PAD was higher than CF (PAD vs. CF, 181 ± 33 vs. 128 ± 28 microvessels/hot 
spot, *P < 0.05), yet the tendency was reversed at day 14 (69 ± 25 vs. 124 ± 25 
microvessels/hot spot, *P < 0.05). DFO has long been confirmed to inhibit the degradation 
of hypoxia inducible factor 1α (Hif-1α), resulting in a promoted regeneration effect. To 
confirm the mechanism, western blot analysis was conducted and semi-quantitatively 
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confirmed this stage specific Hif-1α expression (Figure 18C). Furthermore, the production 
of vascular endothelial growth factor (VEGF), as a downstream effector of Hif-1α, 
consequently exhibited a similar tendency (Figure 18D). 
 
Figure 18. (A) Quantification of the wound area of different groups at different days by using 
Image J software. (B) Semi-quantitative micro-vessel density of different groups at day 
7 and day 14. (C) Western blot analysis of Hif-1α at different healing stage. (D) 
Immunohistochemical staining of VEGF within the wound sites at 7 d or 14 d after 
treatment with different formulations. All scale bars are 100 μm. All the error bars 
indicate the SD value (n = 5). *p < 0.05 and **p < 0.01.  Figures were reprinted with 
permission from publication IV. 
5.5 Biological response of different PSi under inflammation (V) 
When applying PSi for DDS fabrication, NPs would ideally accumulate within lesion 
sites, and the interaction between DDS and lesion sites might alter the biocompatibility of 
the materials and affect the disease outcome. Therefore, it would be valuable to investigate 
the immunomodulatory and biological effects of different PSi within pre-existing lesion 
sites, and explore the potential mechanisms. 
5.5.1 Effects of different PSi on acute liver inflammation 
Three different PSi NPs, namely TO, TC and Un, were investigated within the current work, 
as they obtained an overall similar size, -potential and porosity, but distinguished surface 
chemistries, representing the majorly applied PSi surface stabilization methods. 
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Considering the high accumulation of PSi NPs in the liver, prior to PSi injection, mice were 
induced with acute liver inflammation (ALI) in order to investigate the biological response 
of different PSi NPs within lesion sites. After 48 h post PSi injection, the whole blood 
analysis was first conducted to evaluate systemic changes associated with blood leukocytes. 
Compared with healthy mice, the ALI group showed a significantly enhanced total white 
blood cells (WBC) number. Notably, compared to ALI group, none of the PSi NPs showed 
further WBC number enhancement (Figure 19A), suggesting a confined secondary WBC 
recruitment effect of the different PSi NPs under the inflammatory conditions. Furthermore, 
ALT and AST values of each sample were measured to examine the hepatic function for 
partly reflecting the inflammation progression after injecting the PSi NPs. Compared to the 
ALI group, PSi administration caused a surface chemistry dependent decrease in the 
AST/ALT value, with Un at high concentration reaching a statistically significant difference 
(Figure 19B). GSH values were further evaluated and the results suggested that TO and Un 
administration significantly attenuated the liver damage (Figure 19C). ELISA assay was 
conducted to further unravel the inflammatory status after PSi injection. The expression 
levels of three main pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) were examined, 
and the results suggested that TO and Un show a significant inflammation attenuation effect, 
whereas this effect was marginally robust from TC (Figure 19D-F). Overall, the results 
suggested that under an inflammatory condition, PSi administration might alter the disease 
outcome and immune response in a surface chemistry dependent manner. 
 
Figure 19. (A) Total WBC numbers of each group. (B) Serum AST/ALT level of each group. 
Quantitative analysis of GSH (C), TNF-α(D), IL-6 (E) and IL-1β (F) within liver tissues 
of each group. All the error bars indicate the SD value (n = 5). *p < 0.05, **p < 0.01, 
***p < 0.005 and ****p < 0.001. 
55 
 
5.5.2 Effects of PSi back bonds on ROS scavenge 
The ubiquitous decline in AST levels and the induced AST/ALT ratio attenuations after PSi 
administration were of interest to us. Considering that the hepatocellular AST is mainly 
presented in the mitochondria, a decline in AST leakage may suggest remitted mitochondrial 
damage, which is usually caused by over-produced ROS.263 The existence of reductive 
SiSi back bonds, which is a unique feature of PSi NPs, may feasibly consume and scavenge 
ROS to proceed with the oxidation process, further forming SiOSi linkages to facilitate 
the hydrolysis and degradation reactions (Figure 20A).264 Therefore, our first hypothesis 
was to investigate whether the reductive PSi back bonds might consume overt ROS and 
further modulate liver damage.  
 
Figure 20. (A) Schematic illustration of the PSi NPs’ degradation process. (B) ROS addition 
enhanced the degradation kinetics of PSi NPs to a different extent. (C) Sequential 
addition of PSi NPs to RAW cells under inflammatory stress showed no effect on 
attenuating the intracellular ROS amount. (D) Co-adding PSi NPs and H2O2 to HepG2 
cells simultaneously showed no effects on reversing the ROS-induced cellular 
apoptosis. (E) Pre-incubating H2O2 containing medium with TO for 24 h could mildly 
reduce the cytotoxicity of H2O2. All the error bars indicate the SD value (n = 5). *p < 
0.05, **p < 0.01, ***p < 0.005 and ****p < 0.001. 
Indeed, the addition of ROS could accelerate the PSi degradation kinetics to different 
extents, and the degradation rate ranking for the different PSi NPs was TO > TC > Un 
(Figure 20B). The variations in degradation kinetics were due to the hydrophobic surface 
of TC and Un preventing the surface wetting. However, this ROS scavenging effect was 
marginally robust under in vitro levels. The intracellular ROS contents of murine 
macrophage RAW cells was highly enhanced after LPS/IFN-γ co-activation, yet the 
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sequential administration of different PSi NPs showed no effect on intracellular ROS 
attenuation (Figure 20C). In addition, PSi showed no effect on reversing the H2O2 induced 
cellular apoptosis (Figure 20D). However, if we pre-incubated PSi with H2O2 containing 
medium for 24 h, further incubating cells with the corresponding pre-treated medium, then 
only TO could mildly ameliorate the toxicity of H2O2 (Figure 20E). This can be explained 
as ROS induced cellular damage that was initiated within 30 min,260 whereas the ROS 
scavenging effect from PSi NPs was a rather slow process, as described above. Overall, our 
results suggested that PSi NPs could consume ROS to undertake an accelerated degradation 
processes. Nonetheless, this effect might only have a sparing effect on modulating the 
inflammatory process in vitro. 
5.5.3 Immune perturbation caused by protein corona formation 
Since the reductive nature of PSi back bonds showed limited ROS scavenging effect 
within a short period, a further mechanism should be proposed to explain the obtained data. 
Previous studies suggested that the immune response of particles could be primed and 
regulated via protein corona formation.265, 266 As such, we hypothesized whether the protein 
corona of PSi NPs might perturb the inflammation process. First, we roughly checked the 
different protein binding patterns of different PSi NPs. Blood plasma from ALI mice was 
collected and incubated with different PSi NPs to form protein corona, and the protein 
corona composition was investigated by SDS-PAGE (Supplementary Figure 4 in 
publication V), confirming the surface chemistry dependent protein binding patterns. 
Protein binding did not only influence the cellular uptake and clearance of the particles 
under inflammatory conditions, but the synchronously captured/absorbed inflammation 
related proteins might also interfere with the inflammatory process, as the biological 
functions of the immobilized proteins/peptides might be altered or even abolished.267-269  
The following experiments were conducted to confirm the hypothesis. DMEM medium 
containing 10% of blood plasma from healthy mice or ALI mice were prepared and referred 
to as healthy medium or ALI medium. As shown in Figure 21A, ALI medium induced an 
pro-inflammatory cascade for murine RAW macrophage cells through increasing the 
phosphorylation of nuclear factor κB (NF-κB) inhibitor κBα (IκBα), enhancing the 
expression of NF-κB subunit transcription factor p65 (RELA). However, pre-incubating 
ALI medium with TO and Un, but not with TC, showed ameliorated NF-κB activations 
compared to blank ALI medium, which was consistent with in vivo results. Further mRNA 
expression levels associated with key pro-inflammatory cytokines were also evaluated via 
quantitative PCR. Consistent with the up-mentioned results, ALI medium enhanced the pro-
inflammatory gene expression (see Supplementary Figure 5b in publication V). However, 
PSi treatment modulated the pro-inflammatory effect of ALI medium to a different extent, 
where TO showed an enhanced IL-6 expression, but a decreased IL-1β expression. 
Meanwhile, TC only reduced IL-1β expression, while Un down-regulated the expression of 
TNF-ɑ and IL-1β (Figure 21B, gene expression levels from blank ALI medium were fixed 
as 1). This phenomenon was most probably induced by the ALI plasma absorption, as sole 
PSi NPs administration exhibited a different expression profile of these genes (see 
Supplementary Figure 5c in publication V). ELISA assay was carried out to observe the 
cytokines release profiles of the macrophages treated with healthy medium, ALI medium, 
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and ALI medium pre-treated and containing different PSi NPs. Similar as described above, 
PSi treatment of ALI medium modulated the pro-inflammatory effect of ALI medium in a 
surface chemistry dependent manner, as TO and Un significantly reduced all the three 
cytokines, whereas this effect was retained from TC (See Figure 5c-d in publication V). 
We further applied isobaric tags for Tandem Mass Tag (TMT) method to unravel the 
composition of each corona complex and in total 4459 types of proteins were identified 
from the corona complex. Among which, 2123 types of proteins with P < 0.05 were 
considered to obtain a significantly altered affinity towards different PSi based on the one-
way analysis of variance (ANOVA), and 1127 of them were mainly captured by TO, 
whereas the corresponding number for TC and Un were 483 and 513. The proteins were 
further classified by their subcellular location based on database for annotation, 
visualization and integrated discovery (DAVID). Noteworthy, the percentage of 
mitochondrial proteins within the TO-corona complex (22.8%) was significantly higher 
than TC-corona (13.9%) and Un-corona (12.5%), and Un obtained high percentage of 
extracellular proteins within its corona complex (TO-corona, 15.1%; TC-corona, 11.0%; 
Un-corona, 28.5%. See Figure 4a in publication V). Mitochondrion has been recently 
highlighted as a key intracellular organelle to release immunostimulatory molecules.270, 271 
It has been previous reported that both whole and fragmented mitochondria had potency in 
eliciting non-infectious inflammatory responses.270 Tissue injury releases mitochondrial 
contents, including proteins and DNA, into the circulation with functionally important 
immune consequences in activating antigen-presenting cells (e.g., dendritic cells and 
macrophages).272, 273 
Under diseased condition, cells would secrete proteins to exert the corresponding 
molecular functions, and the binding between these proteins with PSi NPs might directly 
disrupt the biological processes. As such, concerning the cellular localization of the proteins 
in corona-complex, extracellular or secreted proteins were firstly filtered to conduct further 
analysis. In total 862 extracellular and secreted proteins were further filtered, and then 
subjected to biological process (BP) and molecular function (MF) annotations to obtain their 
biological roles. Among which, the most significant enrichments of biological process were 
response to stimulus, immune system process and locomotion; the top 3 significant 
enrichments of molecular function molecular function modulator, ligand binding and 
chemoattractant (Figure 21C), as such, confirming the pro-inflammatory properties of the 
captured proteins within the corona-complex. Within the 862 types of proteins, 244 of them 
were directly associated with inflammatory cascade and obtained enough abundance in all 
three types of corona-complex for conducting relative quantification, and 208 identified 
proteins with P < 0.05 were considered to obtain a significantly altered affinity between 
different PSi (Figure 21D). Based on the relative abundance comparison, 84 types of 
proteins were mainly enriched in TO-corona and the corresponding number for TC-corona 
and Un-corona were 33 and 91. This was consistent with the up-described in vitro and in 
vivo results as TO and Un showed more significant immune perturbation effects than TC. 
Overall, the current study highlighted the altered biological responses of PSi NPs under 
pathological condition, providing insights for further evaluating the biocompatibility and 
immunogenicity of other NPs for biomedical usage, as such facilitating the successful 
clinical translation of nanomaterials.  
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Figure 21. (A) The effects of healthy, ALI and PSi-treated ALI media on modulating the NK-κB 
signaling pathway in RAW macrophage cells. (B) qPCR results delineating the pro-
inflammatory genes expression level in RAW macrophage cells after healthy, ALI and 
PSi-treated ALI media treatment. (C)  The GO term enrichment of 
extracellular/secreted proteins in NPs-corona complex. (D) Heat map of 244 pro-
inflammatory extracellular/secreted proteins in NPs-corona complex. Log-
transformed normalized peak intensities of proteins in each samples were 
expressed using red, black, or green colors in a heat map (n = 3). 
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6 Conclusions 
In this dissertation, both chemical modification and physical encapsulation methods were 
applied to prepare on-demand PSi-based nanohybrids with responsiveness towards specific 
biological conditions according to the disease characteristics, thus rendering precise control 
over the loading and release of drugs with different physiochemical properties at desired 
sites. Convergence of multi-functionalities were achieved within a single nanocarrier by 
simultaneously incorporating bio-imaging or theranostics modalities, thus shedding light on 
the potential for multimodal therapeutics. 
First, a hydrophilic anti-cancer drug, DOX, was efficiently loaded into a PSi-based pH-
responsive DDS. Inspired by the structure of dopamine, a derivative of an anti-cancer 
flavonoid was synthesized to modify PSi, and further bind with iron ions. A pH-responsive 
DOX release was achieved via metal-chelation bond breakage and the release process was 
monitored via fluorescence imaging. 
Next, to enhance the tumor targeting ability of a DDS, a specific CA IX targeting ligand, 
VD11-4-2, was conjugated to PSi. A pH-responsive DOX release behavior was achieved, 
due to the special fluorescence spectrum of VD11-4-2, and the DOX release was also 
feasibly monitored by the FRET effect. 
To encapsulate a hydrophobic drug, a microfluidic-assisted nanoprecipitation method 
was employed to produce PSi/Au co-encapsulated nanohybrids. PSi enhanced the loading 
efficiency of the regenerative drug, while Au was applied for lesion-specific CT imaging. 
The outer polymer matrix promoted the monodispersity and tailored the release behavior of 
the system in a pH-dependent manner. The yielded nanohybrids prominently reduced liver 
damage, improved biosafety by illustrating the liver damage extent, and showed the systems 
to hold great promise for further personalized treatment. 
The co-loading of both hydrophilic and hydrophobic drugs was achieved by fabricating 
an oxidation/acid dual-responsive nanohybrid/ark system. The microfluidics-produced PSi-
based nanohybrids endowed a system with an orchestrated cascade from wound detection, 
ROS scavenging, drug release, and hydrogel formation. The drug release behavior imitated 
the dynamic wound healing process, thus rendering an enhanced bio-mimetic regeneration, 
which demonstrates great potential for diabetic wound healing. 
Finally, the immunogenicity and biocompatibility of different PSi under pathological 
conditions were evaluated. The PSi surface chemistry dependent inflammatory damage 
amelioration was confirmed to be in virtue of the pervasive, yet miscellaneous protein 
corona formation, where a myriad of different proteins were bound to different PSi, 
rendering a perturbation to the inflammatory process. 
Overall, several promising PSi-based DDS with multi-functional modalities and on-
demand control over drugs release profiles were prepared and characterized. With current 
works emphasizing the feasibility and advantages in different bio-medical applications, 
further efforts are still required, e.g., on exploring the potential process and mechanism of 
the successful core/shell nanostructure formation via microfluidics assisted 
nanoprecipitation method, further expanding applications in encapsulating biological 
compounds, such as peptides/proteins, RNA/DNA and even cells. 
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